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CHAPTER 1: Introduction 
Introduction 
. .by small and simple things are great things brought to pass." 
Alma 37:6, The Book of Mormon. 
The dynamics and potential of something as small as a protein molecule are 
illustrated in this quote from the Book of Mormon, used by Garrett and Grisham (1999). 
Proteins establish our very being. They regulate our development, our maintenance and even 
our decomposition. At the molecular level they are responsible for numerous dynamic 
processes in cellular maintenance and growth. At the very heart of all these processes lie the 
transcription factors. The primary function of transcription factors is to initiate and regulate 
gene expression, the first process that eventually leads to protein production. 
Gene regulation is a highly complex process. Mechanisms of regulation can be as 
simple as competition between two related transcription factors for a common binding site. 
On the other hand, they can be as complicated as multiple cascading pathways triggered by a 
variety of signals to initiate a response that depends simply upon cell type, spatial orientation 
within a tissue, or even the timing of a particular developmental event. Multiple families of 
transcription factors have been described including the Homeobox or Hox genes (review by 
Schughart et al., 1988), the Sox family (review by Kamachi et al., 2000), the Pax family 
(review by Noll, 1993), and the Fos and Jun families (review by Kaminska et al, 2000), 
among others. 
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Just over a decade ago a new family of transcription factors was described, 
collectively named the T-box (Tbx) family (Bollag et al., 1994). Work over the past decade 
has revealed much about T-box proteins, and a number of family members have been added 
to the list. At present over 20 mammalian T-box genes have been identified. Furthermore, 
T-box genes have been described for a broad range of species from hydra to humans (reviews 
by Papaiaonnou, 2001; Tada & Smith, 2001). 
Studies of T-box genes have uncovered multiple functions, a handful of interactions, 
and even human syndromes that result from mis-regulation of protein function (review by 
Packham & Brook, 2003). The development of the heart has been a primary focus of T-box 
protein study because of the number of T-box proteins expressed during cardiogenesis 
(reviews by Ryan & Chin, 2003; Plageman & Yutzey, 2005). Furthermore, congenital 
malformations of the heart have been associated with T-box genes (reviews by Plageman and 
Yutzey, 2005; Packham and Brook, 2003). 
Nearly 40 thousand children are born each year with congenital heart defects (CHD) 
and infant mortality rates are higher for CHD than any other birth defect (American Heart 
Association, 2005). Although advancements in the medical field have improved life span 
and quality of life for children with heart defects, the costs of surgery alone exceed 2 billion 
dollars each year (American Heart Association, 2005). Although genetic defects are the 
primary cause of CHD, only a handful of genes have been directly tied to CHD, including 
TBX5 (Basson et al., 1997) and TBXl (Xu et al., 2004). Much is still unknown about Tbx 
proteins and their functions, which makes them prime candidates for further identification of 
CHD associated genes. 
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Thesis overview and organization 
The overall focus of this project included the following two objectives: 1) 
identification of the domain(s) of Tbx2 responsible for repressive activity and 2) 
identification and characterization of proteins that could interact with Tbx2. The function of 
Tbx2 as a repressor of transcription has been thoroughly described in the literature; however 
the protein itself had not been characterized. A putative repression domain was identified 
based on homology to other proteins; however, additional reports suggested that this putative 
domain was not required for Tbx2-induced repression. Furthermore, it has been suggested 
that protein-protein interactions are necessary for T-box protein functions. However, very 
few protein-protein interactions have been described for T-box proteins. Recently, three 
independent interactions for Tbx2 were described in the literature. 
This dissertation is written in an alternative format. Chapter One includes a general 
introduction and review of the literature. Chapters Two and Three are written as manuscripts 
for the journals Gene and BioMed Central: Journal of Biology, respectively. Chapter Two 
was co-authored with Dr. Jim Reecy. I wrote the introduction as well as my methods and 
results, while he included the abstract and the methods and results of the other researchers. 
Together we wrote the discussion and conclusions. The second chapter has already been 
published in Gene, and addresses the first objective of this research—the identification of 
functional domains within Tbx2. For my contribution, I broke down Tbx2 into individual 
domains, fused each domain to Gal4 DNA binding domain and assayed for its ability to 
regulate gene transcription. Deletion assays and analysis of the T-box domain were 
collectively accomplished by Honghua Zhou, Yvette Chin and Karen Langner. The second 
objective, identification of proteins that interact with Tbx2, is included in Chapter Three in 
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manuscript form for submission to the BioMed Central: Journal of Biology. The in situ 
hybridization assays were carried out by Mary Sue Mayes while I performed the remaining 
experiments and the analyses included in Chapter Three. In addition, other than suggested 
editing revisions by Dr. Reecy and members of my committee, I wrote Chapter Three in its 
entirety. Chapter Four includes general conclusions and implications of this research for 
future work. The main chapters are followed by two appendices that include additional work 
to supplement the research presented in Chapter Three. This work was aimed at the further 
characterization of the protein interactions identified in Chapter Three with respect to 
functions in gene regulation, cellular proliferation and protein localization. 
Literature Review 
Heart development 
The heart is the first organ to form during embryonic development, arising from the 
anterior region of the lateral plate mesoderm. Cells destined to become the heart form a 
crescent shaped region, known as the cardiac crescent, just anterior to Henson's node. It is 
believed that the precardiogenic mesoderm is induced by the underlying endoderm 
(Schultheiss et al., 1995). Although the exact signals required to induce cardiogenesis are 
unknown, transforming growth factor (TGF)-P family members appear to play a major role in 
this induction. For example, ectopic addition of bone morphogenic proteins (BMP)-2, -4 and 
-7 was able to induce cardiac specific genes Nkx2.5 and GAT A4 (Schultheiss et al., 1997, 
Andree et al., 1998). Addition of BMP-2 agonist, on the other hand, had a profound 
inhibitory effect on Nkx2.5, eHAND and MefZA during cardiogenesis (Schlang et al., 2000). 
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The paired ends of the cardiac crescent give rise to bilateral heart tubes from the 
splanchnic mesoderm. These tubes migrate together and fuse to form a single linear heart 
tube that consists of inner endocardial and outer myocardial layers (Manasek, 1968). As the 
linear heart tube is formed, distinct cardiac regions begin to develop in a sequential fashion 
along the anterior-posterior (AP) axis (DeHaan, 1965). The sequence of regional 
development in the linear heart tube begins with the right ventricle, followed by the left 
ventricle, the atrio-ventricular canal (AVC) and the presumptive atria. The final segment to 
form is the conotruncus, which consists of the outflow tract and will eventually become the 
pulmonary and aortic trunk. Interestingly, this segment, though last to form, actually 
develops just anterior to the ventricular region of the heart tube (DeHaan, 1965). 
In order for the linear heart tube, with both a common atria and ventricle, to develop 
into the four-chambered heart, a great deal of spatial reorganization must take place. The 
primary method of this rearrangement involves the looping of the heart to the right. Control 
of this process requires a number of complex signals to allow for spatial repositioning and 
reconstruction in order to achieve proper alignment of the heart chambers. Chamber 
alignment is followed by septation of the adjacent chambers and valve formation (De la Cruz 
& Markwald, 1998). It was suggested that the heart is actually a modular organ that, over 
time, has developed additional layers of complexity as it has evolved. Mutations in mice and 
fish have illustrated the "regional" affects of specific genes that give support to this idea of 
modularity in cardiac development (Fishman & Chien, 1997; Fishman & Olson, 1997). 
General eukaryotic transcription 
There are essentially two main levels of gene transcription, basal transcription, and 
gene specific transcription. Basal transcription refers to the level of gene activation induced 
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by RNA polymerase II (PolII) and the general transcription factors which are required for 
transcription to occur. RNA PolII is necessary for messenger RNA initiation and synthesis 
(review by Choder, 2004), while the general transcription factors (TFII) are needed to recruit 
RNA PolH to the promoter (Weaver, 2002). 
Many of the TFIIs contain multiple subunits. For example, one subunit of TFIID is 
the TATA-binding protein (TBP), which binds the TATA-box to allow formation of a pre-
initiation complex on the promoter (Weaver, 2002). A second subunit, the TBP-associated 
factor (TAF) TAFn250, appears to act as an assembly factor for the other TAFs to build 
upon. In addition, TAFn250 has histone acetyltransferase (HAT) and kinase activities, which 
can modify the chromatin to remodel it and subsequently regulate gene transcription 
(Weaver, 2002). Pham & Sauer (2000) reported that in Drosophila, TAFn250 could also 
ubiquitinate histone 1 (HI), which resulted in subsequent gene activation. 
The remaining TFIIs serve a variety of other functions. To stabilize the PolH 
complex, TFIIB acts as a linker between TFIID and TFIEF, while TFILA stabilizes the 
interaction of TFIID with DNA. Helicase activity is demonstrated by TFIIH, which allows 
for DNA strand separation and formation of the transcription bubble. In addition, TFIIH is 
required for promoter clearance of the PolII complex, as is TFIEE (Weaver, 2002). These 
ubiquitous factors work together to induce a basal level of transcription that is then modified 
by gene specific transcriptional regulators. 
Transcription is further regulated to elicit a cell or tissue specific response. Enhanced 
regulation is accomplished by gene specific transcription factors that bind to cz's-acting 
elements along the DNA, either in the promoter or in enhancer regions (review by Villard, 
2004). These transcription factors can form complexes to work in combination with each 
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other and with the general transcription factors to either increase gene activity, or to repress it 
(review by Villard, 2004). Furthermore, because they can interact in complexes, not all 
transcription factors need to bind DNA directly to regulate promoter activity. For example, 
Wheeler and colleagues (2002) demonstrated that the Drosophila repressor protein Runt 
could regulate the expression of the engrailed gene through an interaction with the DNA-
bound protein Tramtrak. Therefore, a promoter may be regulated differently in different cell 
types as a result of different complements of proteins present. 
Nkx2.5 regulation 
Transcriptional specificity of a tissue can be illustrated with one of the earliest 
cardiogenic markers, the transcription factor Nkx2.5. Murine Nkx2.5 was first cloned and 
described by Lints and colleagues (1993). Expression of Nkx2.5 was observed early in 
embryogenesis and solely in the developing heart and pharyngeal arches until approximately 
embryonic day 11.5 (ell .5). At subsequent stages of embryogenesis, Nkx2.5 was expressed 
in the tongue, stomach and spleen (Komuro and Izumo, 1993; Lints et al., 1993). 
Two separate Nkx2.5 promoters upstream of alternatively spliced exons, which were 
shown to drive expression of Nkx2.5 in a tissue specific manner, have been identified in a 
promoter/enhancer region that spans 10.7 kb (Reecy et al., 1999). For example, a LacZ 
reporter transgene driven by one promoter was expressed in a restricted pattern in the heart. 
In contrast, expression of LacZ under control of the second promoter was absent from the 
heart, but observed in the developing pharynx, thyroid, and stomach (Reecy et al., 1999). 
The Nkx2.5 promoter/enhancer has not been fully characterized, but a few regulators of 
Nkx2.5 expression have been described. For example, BMP-4 was shown to activate Nkx2.5 
in cardiomyogenesis (Jamali et al., 2001). In addition, a 505 bp regulatory element that 
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contained paired GATA consensus sites has been identified. This GATA regulatory element 
was able to activate a LacZ transgene in vivo, but a similar element in which the GATA sites 
had been mutated could not (Searcy et al., 1998). Furthermore, in cooperation with the 
cardiac specific transcription factor, GATA-4, Nkx2.5 was shown to modestly upregulate its 
own activity, in vitro (Reecy et al., 1999). 
Not only is Nkx2.5 regulated in a tissue specific manner, but it in turn acts on tissue 
specific targets. For example, Nkx2.5 has been shown to activate the expression of a number 
of cardiac genes including: atrial natriuretic factor (ANF) (Tanaka et al., 1999; Habets et al., 
2002; Plageman & Yutzey, 2004), alpha-cardiac actin (Chen and Schwartz., 1996; Sepulveda 
et al., 1996) and connexin 40 (Cx40; Linhares et al., 2004). Taken together, these studies 
illustrate how tissue specific gene regulation can occur, both upstream and downstream of a 
particular transcription factor. 
The T-box family 
The T-box family is named for its founding member 'T' (for tail), also known as 
Brachyury (Greek for short tail). Brachyury was first identified in a genetic screen in 1927 
(Dobrolvskai-Zadavskaa). Dobrolvskai-Zadavskaa (1927) observed that heterozygous 
mutations in the Brachyury gene resulted in a shortened and often kinked tail,while embryos 
homozygous for mutations in Brachyury died in utero. Embryonic lethality was due to 
abnormal posterior mesoderm development. Specifically, homozygous mutant embryos 
lacked the notochord and somites posterior to somite 7 were either highly abnormal or 
altogether absent (Chelsey et al., 1935, Gluechsohn-Schoenheimer, 1938; Gruneberg, 1958). 
Brachyury was positionally cloned (Hermann et al. 1990), and subsequently identified as an 
activator of gene transcription (Kispert et. al., 1995). A few years later, Bollag and 
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colleagues (1994) identified additional proteins that contained a similar motif to the DNA 
binding domain of Brachyury, and thus the T-box family was formed 
T-box characterization and DNA binding 
The primary characteristic of the Tbx family is a conserved DNA binding domain that 
contains approximately 180-200 amino acid residues known as the T-box (Agulnik et al., 
1996). A new protein family was first suspected when Brachyury was cloned, because the T-
box sequence indicated a novel DNA binding domain. The protein-DNA interaction was 
characterized by x-ray crystallography analysis with Xbra, the Xenopus homologue of 
Brachyury, bound to the palindromic sequence ATTTCACACCTAGGTGTGAAATT 
(Muller and Hermann, 1997). The T-box was shown to contact the DNA in both the major 
and minor grooves, with the majority of protein-DNA contacts found in the minor groove. 
The third helix of Xbra actually bridged the DNA backbone to contact both the major and 
minor grooves. Furthermore, in contrast to other DNA binding domains, interaction with the 
T-box did not bend the DNA (Muller and Hermann, 1997). 
Even though T-box proteins can bind the same palindromic T-element, there appears 
to be some specificity in the ability and manner of interaction between T-box proteins and 
the T-element. For example, Xbra was shown to bind as a dimer to the palindromic T-site 
(Muller and Hermann, 1997). Dimer formation of Xbra was supported when incubation of 
equamolar amounts of Xbra and DNA resulted in a shift of only 50% of the DNA, as 
demonstrated by electromobility shift assay (EMS A) analysis (Muller & Herrmann, 1997). 
Dimerization of the human homologue was observed in other studies, which strengthened the 
hypothesis that Brachyury functions as a dimer (Papapetrou et al., 1997). 
On the other hand, Sinha et al. (2000) demonstrated that TBX2 bound the 
palindromic DNA element as a monomer, not a dimer. Dimerization of the Tbx2 proteins 
was expected to yield three distinct bands, the truncated and full-length homodimers plus an 
intermediate shift that would have resulted from heterodimer formation (Sinha et al., 2000). 
However, results from EMSA experiments in which truncated Tbx2 protein was co-
expressed with full-length protein yielded only two shifted bands. Furthermore, Tbx2 was 
able to bind the sequence GTGTGA and repress the melanocyte specific TRP-1 promoter; 
this DNA element corresponded with a minimal portion of half of the palindromic brachyury 
site (Camera et al., 1998). The consensus sequence GTGTGA has become known as the T 
half-site (T/2 site), and downstream targets that contain this sequence in their promoter 
regions have been identified (Sinha et al., 2000; Prince et al., 2004). 
It has been reported that all T-box proteins examined could bind the T/2 site (review 
by Wilson and Conlon, 2002). However, the ability of T-box proteins to bind the T/2 site 
depends on two factors. First, the protein-DNA interaction appears to depend on overall 
protein sequence or structure. In other words, different Tbx proteins will bind the T/2 site 
differently. For example, TBX2 interacted with the T/2 site more efficiently than TBX1 or 
Xbra (Sinha et al., 2000). Although TBX1 could bind individual T/2 sites, it bound the T/2 
site less efficiently than the palindromic site. However, TBX1 could bind multiple T/2 sites 
placed in tandem quite well (Sinha et al., 2000). In addition, an arginine residue within the 
T-box domain appears necessary for the T-box to bind the consensus site. Muller and 
Hermann (1997) showed that amino acid 67 (an arginine residue) makes direct contact with a 
guanine nucleotide base in the major groove of the DNA. Sinha and colleagues (2000) 
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demonstrated that substitution of argl22 in TBX2, which corresponds to arg67 of Xbra, 
abrogated the ability of TBX2 to bind DNA. 
Secondly, changes in the T/2 site have been associated with differences in the ability 
of Tbx2 to bind the DNA. Carriéra and colleagues (1998) demonstrated that methylation of 
the guanine at position 3 (GTGTGA) interfered with the ability of murine Tbx2 to bind the 
consensus sequence. Furthermore, they showed that Tbx2 could bind, though to a lesser 
degree, the variant sequences GGGTGA and GTGTTA, in vitro. These sequences contained 
substitutions at positions two and five, respectively (Camera et al, 1998). In addition, Tbx2 
has been shown to repress the tumor suppressor pl4ARF through a modified T site— 
CTGCTCACCTCTGGTGCCAAA (Lingbeek et al., 2002). 
Nuclear localization of T-box proteins 
To bind DNA, T-box proteins need to get into the nucleus. T-box proteins appear to 
contain nuclear localization signals (NTS) to achieve this purpose. To date, NTS s have only 
been described for two T-box proteins, TBX 1 (Stoller & Epstein, 2005) and TBX5 
(Collavoli et al., 2003; Zaragoza et al., 2004), although conservation of these signals has 
been shown for other T-box proteins as well. Stoller and Epstein (2005) characterized a 
novel NTS located at the Carboxy-terminus of the TBX1 protein, which appears to be 
conserved among a handful of T-box proteins, including Tbx 10 and Brachyury. Collavoli 
and colleagues (2003) identified two separate signals in TBX5 (NLS1 and NLS2) which, 
when independently fused with GFP, could partially target it to the nucleus. Fusion of both 
signals with GFP resulted in robust nuclear localization of GFP (Collavoli et al., 2003). 
Zaragoza and colleagues (2004) reported that deletion of residues 325-327 from a GFP-
TBX5:239-379 fusion protein, which contained NLS2, resulted in mislocalization of GFP to 
the cytoplasm. Although NLS2 is also highly homologous between species, it is not 
conserved within the T-box family, with the exception of TBX4, the closest related family 
member to TBX5 (Collavoli et al., 2003). The NLS1, on the other hand, lies within the T-
box domain and is highly conserved in TBX1, TBX2, TBX3, TBX4, TBX 10 and TBX22. 
Furthermore, this region is identical across a handful of model organisms including man, 
mouse, Xenopus and chick (Collavoli et al., 2003). Consistent with these findings, Sinha and 
colleauges (2000) demonstrated that full length Tbx2 and a Tbx2 deletion which contained 
only the T-box, localized to the nucleus of HEK293 cells. 
Transcriptional regulation via T-box proteins 
The T-box family is a class of transcription factors that includes both transcriptional 
activators and repressors. Brachyury was the first member of the family recognized as a 
transcription factor. Kispert and colleagues (1995) showed that T protein could drive 
transcription of a reporter gene that contained the palindromic T-element in the promoter 
sequence. Many other family members have since had various transcriptional roles defined 
(review by Tada & Smith, 2001). Most T-box proteins that have been examined could, like 
Brachyury, activate gene transcription. TBX5 for example, was shown to activate ANF 
transcription; interestingly, in cooperation with another transcription factor, either Nkx2.5 or 
G AT A4, TBX5 activation of ANF was synergistic (Bruneau et al., 2001; Fan et al., 2002; 
Plageman & Yutzey, 2004; Garg et al., 2004). Recently, Tbxl was reported to activate 
fibroblast growth factor 10 (Xu et al., 2004). In addition, domains capable of transactivation 
have been identified in Tbx2 (Paxton et al., 2002) and Tbx20 (Stennard et al., 2003). 
The majority of T-box proteins have been characterized as transactivators. However, 
there are a few repressors of gene transcription. Tbx2, Tbx3, ET (the Xenopus ortholog of 
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Tbx3) and Tbx20 have been shown to repress gene activity. Plageman & Yutzey (2004) 
showed that while Tbx5 activated ANF expression, Tbx20 repressed ANF expression. 
Furthermore, a repression domain was identified at the carboxy-terminus of the Tbx20 
protein (Stennard et al., 2003). The three remaining T-box repressor proteins, TBX2, TBX3 
and ET are all highly related. TBX2 and TBX3 are considered paralogs that resulted from 
unequal crossing-over and gene duplication (review by Papaiannou, 2001). The ET protein 
in Xenopus was cloned, sequenced and characterized as an ortholog of TBX3 (He et al., 
1999). Comparison of TBX2, TBX3 and ET protein sequences identified a conserved 
domain (He et al., 1999), carboxy-terminal to the T-box domain, which could repress 
transcription (Paxton et al., 2002). Deletion of this domain from TBX2 resulted in the 
inability of TBX2 to repress transcription (Sinha et al., 2000). On the other hand, fusion of 
this domain to a Gal4-DNA binding domain repressed a Gal4 responsive reporter gene 
(Paxton et al., 2002). Furthermore, Tbx2 repression was also dependent on its ability to bind 
the DNA. A mutant Tbx2 that could no longer bind DNA was also unable to repress gene 
activity (Sinha et al., 2000). 
It is interesting to note that Tbx2 and Tbx20 contain both activation and repression 
domains (Paxton et al., 2002; Stennard et al., 2003). This dual functional has been 
demonstrated for Tbx2. Tbx2 was initially characterized and classified as a potent 
transcriptional repressor. The first indication that Tbx2 could transactivate gene transcription 
was reported when Chen and colleagues (2001) analyzed a microarray in which 107 genes 
were up-regulated and 66 were down-regulated by a two-fold or greater difference. They 
also showed that regulation differed dependent on cellular context (Chen et al., 2001). 
Subsequently, a small transactivation domain was identified in the amino-terminus of the T-
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box which gave variable expression, and which appeared to depend on promoter context 
(Paxton et al., 2002). In an attempt to identify Tbx2 targets responsible for cell toxicity, Butz 
and colleagues (2004) identified a handful of genes that were activated, but none that were 
repressed. Barron and colleagues (2004) recently demonstrated that Tbx2 up-regulated the 
serum response factor (SRF) promoter; furthermore, Tbx2 could synergistically up-regulate 
the SRF promoter in cooperation with TIP60—a histone acetyltransferase. 
Expression patterns of T-box genes 
T-box gene expression patterns are very dynamic and have been observed in a 
number of tissues and throughout various stages of embryogenesis. For example, Brachyury 
expression was visualized along the early primitive streak (review by Showell et al., 2004). 
Expression of Tbx20 was found in the extra-embryonic tissues, such the allantois, amnion, 
and chorion, and in the developing heart (Kraus et al., 2001). Tbx4 expression was also 
observed in the allantoic membrane (Naiche & Papaioannou, 2003). 
Perhaps the best examples of the dynamics of embryonic T-box expression patterns 
were observed throughout development of the limbs and heart. In development of both 
systems, members of the T-box family initiated broad expression patterns early on, which 
became refined as organogenesis proceeded. In limb development for example, Tbx2, Tbx3, 
Tbx4 and Tbx5 were somewhat broadly expressed in the early limb buds and became more 
defined as development progressed (Gibson-Brown et al., 1998; Isaac et al., 1998). 
Similarly, Tbx2, 3 and 5 were broadly expressed in the cardiac crescent, and became more 
restricted in their expression as the heart began to fold. As the heart looped, Tbx3 expression 
was lost; Tbx2 was observed in the AVC, the inflow tract and the outflow tract (OFT); and 
Tbx5 was restricted to the atria and left ventricle (Yamada et al., 2000). 
T-box gene expression throughout limb development 
In the developing chick, Gibson-Brown and colleagues (1998) observed that at 
Hamburger-Hamilton (HH) stage 15 Tbx2 was expressed throughout the flank mesoderm, 
from somites 4 to 24, with the highest level of expression found at presumptive limb buds. 
Tbx3 was also expressed in this region with a slightly narrower pattern, between somites 10-
23. As the limb buds began to develop, Tbx2 was expressed in both the anterior and 
posterior regions along the entire length of the limb buds. In contrast, Tbx3 was expressed in 
the posterior region of the limb bud at HH stage 19 and then in the anterior portion of the 
limb bud at HH stage 21. Later, expression was observed in the interdigital regions of both 
fore and hindlimbs. Throughout HH stages 20-25, Gibson-Brown and colleagues (1998) 
observed Tbx2 expression in the apical ectodermal ridge (AER). Interestingly, Tbx2 was the 
only T-box gene expressed in the AER. Very similar expression patterns were observed in 
Xenopus in which both Tbx2 and Tbx3 were expressed in the anterior and posterior regions 
of the developing limb buds. Initially, expression was symmetrical, with a subsequent loss of 
expression in the anterior region of the limb bud, and the appearance of Tbx2 and Tbx3 
expression within the interdigital regions (Takabatake et al., 2000). 
The expression of Tbx5 and Tbx4 appeared to be limb specific. Tbx5 was strongly 
expressed throughout the forelimb of the chick from HH stages 17-23, while Tbx4 was 
observed in the hindlimb from HH stages 19-26 (Gibson-Brown et al., 1998). Isaac and 
colleagues (1998) reported that under specific conditions they were able to visualize weak 
expression of Tbx4 in the wing, but only some of the time. At later stages of development, 
strong Tbx4 expression was visualized in the interdigital regions of the hind limb (Gibson-
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Brown et al., 1998). Like the chick, Xenopus Tbx4 and Tbx5 were expressed in a limb 
specific manner (Takabatake et al., 2000). 
The expression of Tbx4 and Tbx5 restricted to the hind and forelimbs respectively, 
indicated a role in limb specification. Such a role was demonstrated in the chick by Takeuchi 
and colleagues (1999) when they showed that ectopic expression of Tbx5 in the hind limb 
region resulted in the development of wing-like structures rather than legs. Similarly, 
misexpression of Tbx4 in the area of the presumptive wing resulted in the development of 
leg-like structures, instead of wings (Takeuchi et al., 1999). 
Naiche and Papaioannou (2004) showed a similar requirement for Tbx4 in the 
development of the murine hind limb. In Tbx4 null mice, mutant embryos died around el0.5. 
At that point in embryogenesis, the hind limb buds had already begun to form. Expiants of 
the limb buds from living mutant embryos were transferred to culture and compared to 
expiants from wild-type siblings (Naiche & Papaioannou, 2004). The authors demonstrated 
that hind limb expiants from wild-type controls, and forelimb expiants from both wild-type 
controls and mutant embryos continued to develop normally. However, explanted hind limb 
buds from murine embryos the lacked Tbx4 failed to develop further in culture (Naiche & 
Papaioannou, 2004). 
T-box gene expression during cardiogenesis 
Expression of Tbx2 in the heart was first reported by Bollag and colleagues (1994). 
They observed Tbx2 expression as early as e9.5. Northern blot analysis showed two Tbx2 
transcripts present in the adult heart (Bollag et al., 1994). Not long after Tbx2 expression 
was reported by Northern blot analysis, in the fetal human heart (Law et al, 1995). 
Homologues of Tbx2 have since been identified in the developing hearts of Xenopus (Hayata 
et al., 1999), Zebrafish (Ruvinsky et al., 2000), and chick (Yamada et al., 2000). In the 
chick, Tbx2 and Tbx3 first appeared at HH stage 5 in the cardiac crescent, the region where 
cardiogenic precursor cells reside (Yamada et al., 2000). Increased expression of Tbx2 was 
observed in the anterior portion of the cardiac crescent, mainly in the endoderm, during HH 
6-7 (Yamada et al., 2000). By stage 8, Tbx2 expression was observed throughout the 
bilateral heart tubes in both the mesoderm and the endoderm. Continued expression was 
visualized throughout this region (HH stages 8-10) as the two tubes migrated together and 
fused into a single linear heart tube. The Tbx3 expression pattern overlapped with that of 
Tbx2, except that expression was virtually lost from the heart after HH stage 10. Expression 
of Tbx2 became more restricted as the bilateral tubes fused and the linear heart tube began to 
loop. At this point, Tbx2 expression was limited to the posterior portion of the heart, with 
further restriction to the AVC as the heart continued to fold (Yamada et al., 2000). 
Tbx5 was expressed at HH stage 5 in the cardiac crescent of the embryo, but its 
presence was restricted to the posterior regions of the crescent, which flanked the node. This 
expression pattern overlapped that of Tbx2, which was expressed throughout the entire 
cardiac crescent (Yamada et al., 2000). By HH stage 8, Tbx5 was highly expressed 
throughout the cardiac mesoderm of the bilateral heart tubes. At HH stage 10, Tbx5 was 
mainly expressed in the developing myocardium near the posterior portion of the linear heart 
tube. Later, as Tbx3 expression was lost and Tbx2 became restricted to the AVC, Tbx5 
expression was observed only in the atria and left ventricle (Yamada et al., 2000). Yamada 
and colleagues (2000) found no evidence of Tbx4 expression in early stages of cardiogenesis 
in the chick. However, in el2.5 mouse hearts, Tbx4 expression was visualized in the 
common atria, which is the region of the developing sinus venosus (Chapman et al., 1996). 
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Developmental significance of T-box genes 
The dynamic expression patterns of the T-box genes throughout embryogenesis 
indicate that they may play significant roles in development. Indeed, various developmental 
functions have been associated with specific T-box genes, such as the requirement of Tbx4 
and Tbx5 for hindlimb and forelimb development, respectively (Takeuchi et al., 1999; 
Rodriquez-Esteban et al., 1999). In addition, a handful of T-box genes have been associated 
with developmental anomalies. The murine example of brachyury was mentioned earlier, in 
which a heterozygous mutation of the T gene resulted tail truncation, while embryonic 
lethality resulted from the homozygous condition (Dobrolvskai-Zadavskaa, 1927). In 
addition, a few clinical syndromes have been associated with human TBXl, TBX3 and 
TBX5 (Yagi et al., 2003; Bamshad et al., 1996; Basson et al., 1997). 
TBXl haploinsufficiency 
Haploinsufficiency of TBXl has been implicated in DiGeorge Syndrome. DiGeorge 
Syndrome is characterized by craniofacial defects, as well as thymus and cardiac 
abnormalities (Lindsay et al., 2001). The syndrome is associated with a large deletion on 
Chromosome 22 (review by Baldini, 2004), where TBXl is encoded, among other genes. In 
mice, haploinsufficiency of Tbx 1 disrupts development of the fourth pharyngeal arch, which 
is characteristic of DiGeorge syndrome (Lindsay et al., 2001; Jerome & Papaioannou, 2001). 
Tbxl null mice have a number of other phenotypic anomalies including: cleft palate, 
cardiovascular anomalies, thymus hypoplasia and craniofacial aberrations, all of which are 
common to DiGeorge Syndrome, (Jerome & Papaioannou, 2001). 
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TBX3 haploinsufficiency 
Bamshad and colleagues (1999) showed that mutations in TBX3 were responsible for 
Ulnar Mammary Syndrome (UMS). Characteristics ofUMS include: shortening of the ulna, 
hypoplasia of the mammary tissue, and abnormal development of the tooth, apocrine gland 
and genitals (Bamshad et al., 1996). Both missense and frameshift mutations within TBX3 
have resulted in virtually the same UMS phenotype (Bamshad et al., 1999). It is believed 
that the various mutations in TBX3 resulted in a nonfunctional protein, which yielded a 
haploinsufficient phenotype. Studies with Tbx3 knock-out mice failed to support the 
haploinsufficiency hypothesis. No abnormal phenotype was observed in heterozygous pups; 
however, embryos homozygous of the null allele had severe abnormalities in both the 
forelimb and the mammary tissue, which are characteristic ofUMS (Davenport et al., 2003). 
Abnormal development of the hindlimb was also observed in Tbx3-null embryos. 
Furthermore, all Tbx3-null embryos died over several days in utero due to insufficient 
development of the yolk (Davenport et al., 2003). 
TBX5 haploinsufficiency 
A third condition, known as Holt-Oram syndrome (EOS), has been tied to 
haploinsufficiency of TBX5. Characteristics of HOS include limb abnormalities and 
congenital heart defects (Li et al., 1997; Bruneau et al., 2001). Basson and colleagues (1999) 
identified different TBX5 mutations that resulted in varied expressiveness of HOS 
characteristics. For example, mutations that resulted in a null allele yielded severe cardiac 
and limb abnormalities while a handful of missense mutations resulted in either more severe 
cardiac anomalies with less severe limb alterations, or vice versa (Basson et al., 1999). 
Recently, seven missense mutations were analyzed for their ability to alter TBX5 function. 
Fan and colleagues (2002) showed that for three of the seven mutations TBX5 1) could not 
bind DNA, 2) lost the ability to activate transcription, 3) was mislocalized within the cell and 
4) had faulty protein-protein interactions. Therefore, it appeared that problems with any of 
these functions resulted to some degree in HOS. 
Additional Tbx mutantphenotypes 
While haploinsufficiency of Tbx5 led to HOS, over-expression of Tbx5 throughout 
the heart tube resulted in loss of ventricular-specific gene expression and retardation of 
ventricular development (Liberatore et al., 2000). In Tbx6-null embryos, two ectopic neural 
tubes formed in place of the somites (Chapman and Papaioannou, 1998). In addition, the 
allantois was stunted, apoptotic and displayed abnormal differentiation in Tbx4-null mice 
(Naiche and Papaioannou, 2003). Thus, it could be concluded from these studies that T-box 
genes play significant roles in embryonic development and organogenesis. 
Tbx2 null mouse 
To date TBX2 associated syndromes have not been identified in humans. Recently 
however, a Tbx2 knockout mouse was generated and described by Harrelson and colleagues 
(2004). The authors reported that loss of Tbx2 resulted in embryonic lethality over several 
days. Mortality in the mutant embryos began to occur at e9.5, and by el4.5 all of the Tbx2-
null embryos were dead (Harrelson et al., 2004). In addition, homozygous mutants exhibited 
cardiac abnormalities at approximately e9.5 and digit duplication at about el3.5 (Harrelson et 
al., 2004). Cardiac abnormalities included a lack of AVC restriction at the looping stage of 
cardiogenesis; the AVC remained relatively open and endocardial cushion (EC) formation 
was compromised in a number of mutant embryos (Harrelson et al., 2004). Embryos 
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heterozygous for the mutation, however, appeared phenotypically normal and viable 
(Harrelson et al., 2004), which indicated that haploinsufficiency may not be an issue for 
Tbx2. However, similar studies with Tbxl haploinsufficiency in mice showed minor 
phenotypic anomalies as compared to the homologous human condition that resulted in 
DiGeorge syndrome. The phenotypic characteristics of mice homozygous for the Tbxl-null 
mutation, however, more closely resembled DiGeorge syndrome characteristics of humans 
(Lindsay et al., 2001). Similarly, mice heterozygous for Tbx3 appeared phenotypically 
normal, while Tbx3-null embryos demonstrated abnormalities characteristic ofUMS 
(Davenport et al., 2003). Therefore, although Tbx2 haploinsufficient mice appeared normal, 
Tbx2-null mice may more closely model a human haploinsufficiency for TBX2. 
Characterization of Tbx2 protein 
The T-box domain of Tbx2 spans amino acid residues 82-285. In addition to the T-
box domain, a C-terminal repression domain was described, based on homology to a 
carboxy-terminal region found in TBX3 and ET (the Xenopus orthologue of TBX3) two 
other repressors in the T-box family (He et al., 1999). Subsequent studies in HEK293 cells 
showed that deletion of the carboxy-terminus of TBX2, after residue 407, alleviated TBX2 
induced repression (Sinha et al., 2000). Sinha and colleagues (2000) mapped a TBX2 
repression domain to residues 407-560, however, this region eliminated the portion of TBX2 
that contained the conserved carboxy-terminal region previously described in ET (He et al., 
1999). These results indicated that either 1) the conserved carboxy-terminal domain was not 
responsible for TBX2-induced repression or 2) a second transcriptional repression domain 
exists in the TBX2 protein (Sinha et al., 2000). Two transcriptional repression domains have 
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since been described, along with a small activation domain, located in the amino-terminal 
region of the T-box (Paxton et al., 2002). 
Reported functions of Tbx2 
Several functions have been reported for Tbx2, including regulation of transcription, 
cellular proliferation, and embryonic development. The most reported function for Tbx2 has 
been repression of gene transcription (Camera et al., 1998; Sinha et al., 2000; He et al., 
1999). Several genes that are repressed by Tbx2 have been identified including ANF (Habets 
et al., 2002), Connexin (Cx)40, (Christoffels et al., 2004), Cx43 (Christoffels et al., 2004; 
Chen et al., 2004), p21WAF1 (Prince et al., 2004), Nmycl (Cai et al., 2005) and Cdkn2a 
(Jacobs et al., 2000). Although Tbx2 has predominately been described as a transcriptional 
repressor, a recent study by Barron and colleagues (2004) showed that Tbx2 activated the 
SRF promoter. Thus Tbx2 has been shown to both activate and repress gene transcription. 
The ability of Tbx2 to regulate transcription has impacted other cellular functions as 
well. For example, Tbx2 was shown to bypass cellular senescence through the down 
regulation of Cdkn2a promoter activity, which subsequently induced cellular proliferation 
(Jacobs et al., 2000). In addition, it was reported that endogenous Tbx2 was necessary for 
the maintenance of cellular proliferation in a B16 melanoma cell line, which resulted from 
the repression of p21 (Vance et al., 2004). On the other hand, Cai and colleagues (2005) 
recently demonstrated that Tbx2 could repress the proliferation factor Nmycl in vivo, and 
proposed that low proliferation in regions of the heart, such as the AVC, resulted from Tbx2 
repression of Nmycl (Cai et al., 2005). 
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Several reports have implicated Tbx2 in cardiogenesis, in addition to its ability to 
repress Nmycl. For example, Tbx2 was shown to repress the heart chamber specific gene 
ANF, which indicated a role for Tbx2 in delineation of the cardiac chambers (Habets et al., 
2002). In addition, loss of Tbx2 resulted in lethality of Tbx2-null embryos, due to cardiac 
insufficiency (Harrelson et al., 2004). Harrelson and colleagues (2004) reported that Tbx2 
was specifically required for proper AVC patterning and development of the OFT. 
Therefore, Tbx2 function appears to have a vital role in the development of the heart. 
Roles of ubiquitination and deubiquitination 
Ubiquitination/Deubiquitination is a very dynamic process that appears to be involved 
in a number of cellular processes. The role of ubiquitin in the proteasomal degradation 
pathway has been the most thoroughly studied. The addition of polyubiquitin chains act as a 
signal for protein degradation by the proteasome. In addition to protein degradation, 
ubiquitination also seems to be involved in transcriptional regulation, development, cell-
cycle progression (proliferation), cellular stress and sub-cellular localization (reviews by 
Jason et al., 2002; Wing, 2003). Though the field of protein ubiquitination has been heavily 
investigated, the reverse process of deubiquitination has received much less attention. An 
expansive family of deubiquitinating proteins (DUBs) has been identified, and has steadily 
grown over the past decade. The DUB family consists of over 90 members, the largest 
enzymatic family in the ubiquitin system (review by Chung & Baek, 1999). Owing to the 
vastness of the DUB family and the diversity of functional roles described, DUB proteins are 
believed to act on very specific substrates. Furthermore, they are thought to be the key force 
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in the maintainence of functions affected by ubiquitination state (review by D'Andrea & 
Pellman, 1998). 
Ubiquitination/deubiquitination in transcriptional regulation 
Ubiquitination of histones affects the regulation of gene transcription. Histone 
modifications play a major role in the regulation of gene activity due to the impact they have 
on chromatin remodeling (review by Jaskelioff and Peterson, 2003). While much is known 
about how acetylation and methylation regulate gene expression, there is little known about 
the role of ubiquitination in this area. Interestingly, even before histone -acetylation and -
methylation were discovered, increased histone-ubiquitination was identified in 
transcriptionally-active versus -inactive chromatin (Nickel et al., 1989). Shortly afterwards, 
Davie and Murphy (1990) reported that ubiquitination of histone 2B (H2B) was maintained 
during gene activation. Furthermore, they reasoned that addition of the large ubiquitin 
moiety prevented chromatin condensation, which allowed for transcription to continue 
(Davie and Murphy, 1990). It was only recently demonstrated, however, that ubiquitination 
was tied directly to regulation of gene transcription. Pham and Sauer (2000) demonstrated 
that the transcription factor TAFII250 was capable of ubiquitination activity. Specifically, 
TAFII250 could monoubiquinate histone 1 (HI), which resulted in increased transcription 
(Pham and Sauer 2000). 
In another study, monoubiquitination of H2B by Rad6 immediately preceded 
activation of the Gall promoter (Kao et al., 2004). Furthermore, Kao and colleagues (2004) 
showed that ubiquitinated H2B was associated with induced and constitutively active 
promoters, but not with silenced promoters. Subsequent recruitment of the Spt-Ada-Gcn5-
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acetyl transferase (SAGA) complex was associated with loss of ubiquitination (Kao et al., 
2004). Daniel and colleagues (2004) reported that the SAGA complex contained a ubiquitin 
protease, Ubp8, which could deubiquitinate H2B. Furthermore, an accumulation of 
ubiquitinated H2B was observed in a Ubp8 deletion yeast strain (Daniel et al., 2004). 
Another aspect of transcriptional regulation via ubiquitination is that chromatin 
modifications appear to occur in a sequential fashion. For example, a mutation in Rad6, that 
prevented ubiquitination of H2B, led to inhibition of methylation at lysine 4 on histone 3 
(Sun and Allis, 2002; Dover et al., 2002). Furthermore, lack of methylation at this residue 
resulted in gene silencing (Sun & Allis, 2002; Dover et al., 2002). This example illustrated 
what has been termed the "Histone Code". The histone code refers to the idea that regulation 
of a particular gene is dependent on the sequence of modifications at the tails of neighboring 
histones (review by Jenuwein & Allis, 2001). Taken together these studies that have looked 
at the role of histone ubiquitination in gene regulation have demonstrated how differential 
ubiquitination of histones could have opposite effects on transcription. 
Ubiquitination and subcellular localization 
Protein modifications have also been shown to affect the subcellular fate of a 
particular protein. Recently, Shcherbik and Haines (2004) reviewed the roles of 
ubiquitination and deubiquitination on the cellular trafficking of transcription factors. One of 
the most studied examples of nuclear import of transcription factors involves the NF-KB 
pathway. When bound to the inhibitory IKB protein complex, NF-KB was inactive in the 
cytoplasm. Polyubiquitination and subsequent degradation of the IKB proteins uncovered an 
NLS in NFKB, which allowed for transportation of NFKB to the nucleus (Shcherbik and 
Haines, 2004). However, ubiquitin may play an even earlier role. Krappmati and Scheidereit 
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(2005) reviewed signaling events of the NFKB pathway that involved ubiquitin, and 
discussed the emerging roles of ubiquitination and deubiquitination on activation of the IKB 
kinase complex, which did not involve proteasomal degradation. 
Deubiquitination and proliferation (cell cycle control) 
Deubiquitination was also shown to affect cellular proliferation through control of the 
cell cycle. Almost a decade ago, the protein DUB-1 was identified in a cytokine inducible 
screen and subsequently cloned (Zhu et al., 1996). Under the direction of a steroid inducible 
promoter, constitutive expression of DUB-1 led to cellular arrest at the G1 phase of the cell 
cycle. Removal of the steroid allowed proliferation to resume (Zhu et al., 1996). On the 
other hand, loss of USP8 by anti-sense RNA expression appeared to inhibit cell cycle 
progression (review by Wing, 2003). A mutant form of Ubp-M (USP16) co-localized to 
mitotic chromatin and led to senescence and apoptosis, which indicated that it too may play a 
role in cell cycle control. The mutant form of USP16 contained a cysteine to serine 
substitution that rendered it catalytically inactive. The inability of USP16 to deubiquitinate 
proteins indicated that DUB activity was required for cell cycle control (Cai et al., 1999; 
review by Wing, 2003). Interestingly, although expression ofUSPl appeared to be cell cycle 
dependent, a comparable cysteine to serine substitution in the active site ofUSPl did not 
appear to affect cell-cycle progression (Nijman et al., 2005). 
The deubiquitinase USP1 
USP1 belongs to a subclass of DUB enzymes known as the ubiquitin specific 
processing proteases (UBP or USP). Murine Uspl was recently identified by the Strausberg 
and colleagues (2002), and is 86% identical at the protein level to the human homologue. 
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Like other UBPs, USPl contains two Ubiquitin Carboxy-terminal Hydrolase (UCH) 
domains, with conserved cysteine and histidine residues present in the active site. These 
domains are characteristic of both the UBP and the UCH subclasses of the DUB family 
(review by D'Andrea and Pellman, 1998). Numerous UBPs/USPs have been identified. 
Reported roles for individual USPs include protein stabilization, targeting proteins for 
degradation, growth control, and disruption of transcriptional silencing (review by D'Andrea 
& Pellman, 1998). Recently, it was demonstrated that UBP45 and UBP69 had antagonistic 
roles in myogenesis (Park et al., 2002). Taken together these results indicate that regulation 
of ubiquitination may play a fundamental role in tissue development. 
Human USPl could deubiquitinate Ub-|3-Galactosidase, and was mapped to 
chromosome 1 (Fujiwara et al., 1998). Just recently a functional role for USPl was proposed 
in the Fanconi Anemia (FA) Pathway. Fanconi Anemia is a genetic disorder characterized 
by a number of symptoms such as chromosomal aberrations, retarded growth and skin 
abnormalities. The main basis for FA was the inability of the cell to elicit proper repair of 
damaged DNA (review by Taniguchi & D'Andrea, 2002). As a result, individuals are 
predisposed to a number of malignant conditions. Within the FA pathway, the protein 
FANCD2 was dynamically regulated by monoubiquitination, which could target it to the 
chromatin when DNA damage occurred (Wang et al., 2004). Nijman and colleagues (2005) 
showed by co-immunoprecipitation analysis that USPl interacted with FANCD2 and that 
knock-down ofUSPl, by RNAi, resulted in accumulation of FANCD2-L (the 
monoubiquitinated form of FANCD2). USPl, therefore, appeared to recycle FANCD2 after 
DNA damage was repaired. In addition to its role in the FA pathway, the authors 
demonstrated that USPl expression was cell-cycle regulated, with increased levels in G1 and 
28 
early S phase that dropped off by late S phase (Nijman et al., 2005). Nijman and colleagues 
(2005) also observed that a GFP-USP1 fusion protein localized to the nucleus. 
Caper-a, a transcriptional and splicing co-factor 
In a yeast 2-hybrid screen of a mouse liver cDNA library, that was designed to 
identify proteins that interact with the general coactivator ASC-2, Jung and colleagues (2002) 
identified two related clones: hCC1.3 and hCC1.4. The proteins encoded by these two 
transcripts were virtually identical in sequence, and reportedly in function. The only 
apparent difference between the two proteins was the presence of six additional amino acids 
in the hCC 1.4 gene product (Jung et al., 2002). Jung and collègues (2002) also reported that 
the murine homologue differed from the human protein at only two residues. 
After analysis of its ability to interact with and influence several transcription factors, 
the hCC1.3 transcript was dubbed CAPER, for coactivator of activating protein-1 (AP-1) and 
estrogen receptors (Jung et al., 2002). CAPER was renamed CAPER-a when a related 
protein with 49% identity, now named CAPER-P, was identified (Dowhan et al, 2005). 
CAPER-a bound to the AP-1 heterodimer, specifically to the c-Jun subunit, and enhanced 
promoter activity (Jung et al., 2002). Both CAPER proteins could bind the alpha and beta 
estrogen receptors to potently stimulate estrogen-induced transactivation (Jung et al., 2002). 
In addition, CAPER-a and CAPER-P stimulated progesterone-induced transactivation by the 
progesterone receptor as well (Dowhan et al., 2005). However, CAPER enhanced activation 
was not observed with the thyroid hormone receptor (TR), which indicated that CAPER 
interaction and coactivation was specific for selected steroid receptors (Dowhan et al., 2005). 
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An inherent transactivation domain was identified in CAPER-a that spanned residues 
291-355 (Jung et al., 2002). In addition to the transactivation domain, characterization of the 
CAPER-a protein identified a serine and arginine (SR) rich region and three RNA 
recognition motifs (RRM) (Jung et al., 2002). CAPER-P also contained the SR domain, but 
only 2 RRMs were present (Dowhan et al., 2005). The combination of the SR domain and the 
RRMs is characteristic of SR splicing factors, which play a role in the mediation of 
alternative splicing in vivo (Tacke and Manley, 1999). Recently, Dowhan and colleagues 
(2005) reported on the similarities of the CAPER proteins to the splicing factors U2AF65 and 
PUF60. Together these proteins appeared to make up a U2AF65-like family of splice factors 
(Dowhan et al., 2005). Northern blot analysis identified a somewhat defined pattern for both 
CAPER molecules demonstrated by multiple transcripts and varied expression from tissue to 
tissue. In contrast, U2AF65 and PUF60 were expressed at constant levels in almost all of the 
tissues analyzed, which indicated that U2AF65 and PUF60 may function as general splice 
factors, while the CAPER proteins may demonstrate more specific roles in developmental 
processes (Dowhan et al., 2005). 
Due to the presence of the SR domain and the RRMs, and their homology to U2AF65 
and PUF60, Dowhan and colleagues (2005) tested CAPER-a and CAPER-P for splicing 
capability. The calcitonin (CT)/ calcitonin gene-related peptide (CGRP) minigene, which 
could generate dual transcripts, was hooked up to an HSV promoter that contained a 
progesterone receptor element (PRE). Dowhan and colleagues (2005) showed that addition 
of progesterone induced a change in the ratio of CT:CGRP transcripts generated. This 
change in transcript composition was further enhanced by the presence of either CAPER-a or 
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CAPER-P (Dowhan et al., 2005). U2AF65 also induced a change in transcript ratio, but could 
do so from both PR-responsive and control promoters, whether or not progesterone was 
present. On the other hand, PUF60 was unable to alter this ratio under any conditions tested 
(Dowhan et al., 2005). 
Implications for this research 
To better understand the role of Tbx2 in cardiogenesis, the functions of Tbx2 need to 
be clarified. Repression by Tbx2 has been demonstrated several times in the literature, but a 
mechanism for how Tbx2 repressed transcription was unknown. Furthermore, there was 
evidence in the literature to suggest that Tbx2 contains multiple domains capable of 
transcriptional regulation. There was a need, therefore, to characterize Tbx2 and identify 
those domains that could regulate gene activity. Since T-box protein functions most likely 
depend on interactions with other proteins, there was also a need to identify proteins that 
could interact with Tbx2. Two proteins studied for their ability to interact with Tbx2 in this 
work included: the deubiquitinase Uspl, and the transcription and splicing co-factor Caper-a. 
There was evidence in the literature that indicated that both of these proteins could 
potentially be involved in gene regulation. Therefore, these proteins were analyzed for their 
ability to interact with Tbx2 and to regulate transcription. 
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CHAPTER 2: Murine Tbx2 contains domains that activate 
and repress gene transcription. 
A paper published in Gene1 
Christian Paxton2'3, Honghua Zhao2, Yvette Chin2, Karen Langner2 and James Reecy4 
Abstract 
T-box (Tbx) genes represent a phylogenetically conserved family of transcription 
factors that play important roles during embryonic development. Tbx family members have 
been shown to either activate or inhibit gene expression. However, little is known about the 
domains within Tbx proteins responsible for mediating gene transcription. While Tbx2 is 
known to repress gene expression, the domain(s) within Tbx2 remains poorly defined. 
Deletion of the carboxy terminus of Tbx2, which contains a domain that is highly conserved 
with Tbx3 and ET, which has been demonstrated to contain a repression domain, only 
minimally diminishes the ability of Tbx2 to repress gene expression. However, in 
combination with the carboxy terminal truncation, deletion of the amino acids located amino 
terminal to the T-box abolished the ability of Tbx2 to repress gene expression. Both of these 
domains were capable of repressing gene expression when linked to the GALA DNA binding 
domain. In contrast to these two repression domains, the T-box was capable of weakly 
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activating gene expression depending on the promoter context. Deletion analysis of the T-
box suggests that this activation domain is located in the amino terminal end of the T-box. 
These results reveal a novel transcription repression domain, confirm the presence of a 
previously implicated domain, and suggest a novel role for the T-box. Taken together, these 
results provide the basis for understanding the molecular mechanism whereby Tbx2 regulates 
gene expression and subsequently control embryonic development. 
1. Introduction 
The T-box gene family today represents a prominent focus of interest in the field of 
developmental biology. The first member of this family to be described was Brachyury, or T 
(Dobrovolskaia-Zavadskaia, 1927). In the heterozygous state, a loss of function mutation in 
Brachyury results in truncated tails in mice. However, animals homozygous for this 
mutation die in utero. Using positional cloning techniques, Hermann et al, (1990) isolated 
Brachyury. Then in 1995, Kispert et al. demonstrated its role as a transcription factor. Over 
the past decade numerous other related genes have been identified in a variety of species (see 
review by Papaioannou and Silver, 1998). 
The T-box family is so named because of a conserved region of approximately 180 
amino acid residues responsible for DNA binding activity (Agulnik et al., 1996). The family 
is broken down further into subfamilies based on expression patterns and evolutionary 
relatedness. Even within subfamilies, similarities are highly conserved between certain 
family members, for instance, in the mouse Tbx2 and Tbx3 are considered gene pairs, as are 
Tbx4 and Tbx5 (see review by Papaioannou and Silver, 1998). Like Brachyury, many of 
these family members have been implicated in genetic developmental syndromes. For 
example, mutations in Tbx3 and Tbx5 lead to the Ulnar-Mammary and Holt-Oram syndromes 
respectively (He et al., 1999; Basson et al., 1997). However, other family members like 
Tbx2 have not yet been implicated with other known genetic syndromes. 
Tbx2 was first cloned and mapped in the human (Campbell et al., 1995). Tbx2 
mRNA expression has been observed in numerous adult tissues of the mouse: lung, kidneys, 
heart, and ovaries (Bollag et al., 1994). Subsequently, mRNA expression was detected 
during embryonic development in the central and peripheral nervous systems, the neural 
retina, and the myotome (Chapman et al., 1996). Recently, Yamada et al. (2000) reported 
that Tbx2 transcripts could be detected during cardiogenesis in the chick and mouse. Tbx2 
transcripts were first present at Hamburger-Hamilton stage 5 in the cardiogenic crescent. 
Transcripts were found initially in the endoderm and subsequently appeared in the mesoderm 
as the bilateral cardiac tubes formed. The cardiac tubes fuse to form a single linear heart tube 
with Tbx2 mRNA found throughout linear heart tube region. As the heart tube begins to fold, 
Tbx2 expression declines until it is restricted to the atrio-ventricular canal (Yamada et al., 
2000), and particularly in the inner myocardium of the AV canal. However, the 
developmental role of Tbx2 has not yet been elucidated. 
Unlike Brachrury, which is a transcription activator (Kispert et al., 1995), Tbx2 is a 
potent repressor of gene expression (Carreira et al., 1998; Sinha et al., 2000). He et al. 
(1999) demonstrated the presence of a conserved repression domain within Xenopus ET and 
its human ortholog Tbx3. Furthermore, this region is highly conserved within Tbx2. 
Possible mechanisms for repression may involve the Groucho/TLE family, which interact 
with DNA binding proteins to repress, rather than by direct DNA binding by family members 
themselves (see review by Chen and Courey, 2000). Another possibility may involve histone 
deacetylation. This mechanism acts via modification of the histone proteins resulting in 
chromatin rearrangements, which strengthen the histone-DNA interactions, making DNA 
less available to transcription factors (see review by Ayer, 1999). However, before the 
mechanism by which Tbx2 represses gene transcription can be identified, the transcription 
repression domain must be mapped in greater detail. As an initial step in this direction, we 
have identified two transcription repression domains within Tbx2 and a weak transactivation 
domain within the T-box. 
2. Materials and Methods 
2.1 Tbx2 expression vector construction 
The pcDNA3 directed wild-type Tbx2 expression vector (pcDNA3-Tbx2; Chen et al., 
2001) was kindly provided by Dr. Roni Bollag. Deletion constructs of Tbx2 were prepared 
by PCR amplification as follows (see Figure 1 for pictorial depiction of Tbx2 expression 
constructs): Tbx2-654 was amplified with primers Tbx2-54U18 (5'-CGC CAT GGC TTA 
CCA CCC-3') and Tbx2-2002L18 (5'-TCG GAG AGC CAG CTC AGG-3'), Tbx2-528 with 
Tbx2-54U18 (5'-CGC CAT GGC TTA CCA CCC-3') and Tbx2-1624L18 (5'-TAG CCC 
GCC TGC GTC CAG-3'), Tbx2-433 using Tbx2-54U18 (5'-CGC CAT GGC TTA CCA 
CCC-3') and Tbx2-1339L18 (5'-CTT GCC CTC ACC CAC GTC-3'), Tbx2-63/345a with 
Tbx2-54U18 (5'-CGC CAT GGC TTA CCA CCC-3') and Tbx2-1075L18 (5'-CGG CTT 
CTC CTC GGC TCG-3'), and Tbx2-63/345b with Tbx2-236U18 (5'-CGG CCA TGG CGG 
GGC TGC-3') and Tbx2-1075L18 (5'-CGG CTT CTC CTC GGC TCG-3'). Amplification 
products were cloned into pcDNA3.1/V5/His-TOPO (Invitrogen). All constructs were 
confirmed by sequencing to insure that no amino acid mutations were introduced. pB-Tbx2 
was constructed by cloning the wild-type Tbx2 coding sequence into pBind (Promega). For 
Tbx2 T-box pBind deletion constructs, Tbx2 sequences were PCR amplified as follows: 
pB:Tbx2-82/285 was amplified with Tbx2-301U18 (5'-GCT CAA GAG CCT GGA ACC 
CGA-3') and Tbx2-914L18 (5'-TTT TCT CCC GAC GGC CGT TC-3'), pB:Tbx2-82/246 
with Tbx2-301U18 (5'-GCT CAA GAG CCT GGA ACC CGA-3') and Tbx2-797L18 (5'-
CTG GGA AGA CAT AGG TGC GG-3'), pB:Tbx2-82/224 with Tbx2-301U18 (5'-GCT 
CAA GAG CCT GGA ACC CGA-3') and Tbx2-731L18 (5'-GGA ATC GCG GCT GGT 
ACT TG-3'), and pB:Tbx2-82/155 with Tbx2-301U18 (5'-GCT CAA GAG CCT GGA ACC 
CGA-3') and Tbx2-524L18 (5'-TAT AGC GGC AGT CAT CGG CA-3'). These 
amplification products were cloned into pT-Adv (Clontech) and subsequently cloned in-
frame into pBind (Promega). All constructs were named based on the first and last amino 
acid residues present. Constructs starting at the wild-type start methionine were named 
solely by the last residue present. 
2.1.1 Generation of pBind:Tbx2 constructs 
To generate pB:Tbx2-515/574, pcDNA3-Tbx2 was digested with Nar I, blunt-ended 
with klenow fragment and cut with Not I. The 180 bp fragment was gel extracted, purified, 
and cloned into pBind (Promega). The 3' most construct which consists of the last 128 
amino acid residues, hereafter referred to as pB:Tbx2-574/701, was made by restriction 
endonuclease digestion of pcDNA3-Tbx2 with Not I and EcoR I, subcloned into pBluescript-
SK+ to pick up additional restriction endonuclease sites, and subsequently cloned into pBind. 
The pB:Tbx2-280/528 fragment was PCR amplified from pcDNA3-Tbx2 using primers 
914U18 (5'-GAA CGG CCG TCG GGA GAA A-3') and 1624L18 (5'-TAG CCC GCC 
TGC GTC CAG-3'). The PCR product was subcloned into pT-Advantage (Clontech) and 
sequenced. pT-Adv-280/528 was cut with EcoR V and Kpn I and subcloned into pBind. T7, 
from the promoter region in the pcDNA3 backbone, and 301 LI8 primers were used for PCR 
amplification of the 5' fragment, using pcDNA3 as a template. The PCR product was 
subcloned into pT-Adv (Clontech) and digested with Bgl II and EcoR V. A 220 bp fragment 
was gel-extracted, purified, and cloned into pBind, which had been cut with BamH I 
(complimentary to the Bgl II cohesive end) and EcoR V. Sequencing of the construct 
showed that a deletion of 72 bp occurred, resulting in a coding sequence for residues 1-87 of 
the mTbx2 protein with a deletion of residues 54-77. Even though residues 78-87 are 
present in this construct they form an overlap with other constructs, which contain some or 
all of this region. Therefore, this construct will be identified hereafter as pB:Tbx2-l/53. 
2.2 Reporter constructs 
The G3PDH-LaBS-CAT reporter construct was kindly provided by Dr. Charles 
Coding. This construct contains a single Tbx binding site cloned 5' of the G3PDH promoter 
(Carreira et al., 1998). G3PDH-G1 and -G5 reporter constructs were constructed by cloning 
either 1 or 5 GAL4 cis-acting elements from pG5-Luc (Promega) 5' of the G3PDH promoter. 
2.3 Transient transfection assays 
CH3/10T1/2 clone 8 cells (ATCC# CCL-226) were grown in Dulbecco's Modified 
Eagles Medium (Life Technologies) supplemented with 10% fetal bovine serum and 
antibiotics (penicillin-streptomycin) at 37 °C and 5% carbon dioxide. Transactions were 
carried out using lipofectamine (Life Technologies), 1 pg G3PDH reporter, Tbx2 expression 
construct, and 400 ng CMVPgal. Cell extracts were prepared from cells 48 hours after 
completion of transfection. Plates were rinsed twice with ice-cold PBS. Rapid lysis buffer 
(Promega) was added to each plate to prepare cell extracts. Extracts were clarified by 
centrifugation at 20,000g for 10 minutes. CAT activities were analyzed with Flash CAT 
(Stratagene). Protein concentrations and Pgal activities were determined as previously 
described (Reecy et al., 1997). CAT values were normalized to the (3-galactosidase activity 
and protein content and expressed relative to empty vector control (pcDNA3 or pBIND). 
3. Results and discussion 
3.1 wild-type Tbx2 represses chimeric promoter activity 
Murine Tbx-2 protein has been shown to function as a transcriptional repressor using 
either endogenous or chimeric promoters (Carreira et al., 1998; He et al., 1999; Sinha et al., 
2000; Jacobs et al., 2000). In contrast, T and Tbx-5 proteins have been shown to function as 
transcriptional activators (Kispert et al., 1995; Hiroi et al., 2001). To identify the 
transcriptional repression domains within Tbx2, we generated a series of carboxy-terminal 
deletion constructs (Figure 1). Wild-type Tbx2 repressed G3PDH-LaBS-CAT promoter 
activity by approximately 10-fold (Figure 2). In contrast, Tbx2 was not capable of repressing 
G3PDH-CAT promoter activity, a reporter construct lacking the cis-acting element to which 
Tbx2 can bind (Data not shown), identical to work reported by Camera et al. (1998). Thus, 
DNA binding activity is required for transcriptional repression. 
Sinha et al. (2000) reported that truncation of Tbx2 at amino acid 407 resulted in loss 
of repressive activity of Tbx2 in 293 cells. However, in our experiments deletion constructs 
Tbx2-433 and Tbx2-345a repressed promoter activity (Figure 2) similar to wild-type Tbx2 in 
C3H 10T1/2 cells. Both of these constructs lack the repression domain reported in Sinha et 
al. (2000). These conflicting results are important in that they suggest two possibilities. 
First, Tbx2 contains more than one domain that is capable of repressing gene expression as 
previously reported (Sinha et al., 2000). Second, they suggest that the molecular mechanism 
whereby Tbx2 represses gene expression differs in different cell types. Consistent with this 
line of reasoning, the borders of the transactivation domain of serum response factor (SRF) 
vary in different cell lines (Johansen and Prywes, 1993; Liu et al., 1993). In addition, the 
ability of SRF to transactivate gene expression is dependent on the availability of accessory 
factors, including SAP-1, Elk-1, and Phox-1 (Schroter et al., 1990; Pollock and Treisman, 
1991; Dalton and Treisman, 1992). The deletion of the 62 amino-terminal amino acids, to 
produce construct Tbx2-63/345b, abrogated the ability of Tbx2 to repress transcription 
(Figure 2). These results suggest that a transcription repression domain is located within the 
amino terminal end of Tbx2. In contrast, the amino-terminal tail of Tbx3 was capable of 
transactivating gene expression in cell culture (He et al., 1999). 
3.2 Promoter context alters the ability of the Tbx2 T-box to regulate gene expression. 
In transfection experiments with G3PDH-LaBS-CAT, the observed response in 
promoter activity to Tbx2-82/285 was variable. In contrast, the response to all other Tbx2 
deletion constructs was very consistent. As G3PDH-LaBS-CAT contained only a single 
Tbx2 cis-acting element and Tbx2-82/285 was limited to only the minimal T-box domain, we 
decided to investigate the relationship of cis-acting elements on the transactivationl 
capabilities of Tbx2. We generated a GAL4 DNA binding domain/Tbx2-82/285 fusion 
construct (pB:Tbx2-82/285). We then tested the ability of Tbx2-82/285 and pB:Tbx2-82/285 
to regulate promoter activity in reporter constructs containing one T-box (G3PDH-LaBS-
CAT) or one or five GAL4 DNA binding domains (G3PDH-1G-CAT and G3PDH-5G-CAT), 
respectively (Figure 3). 
Binding of Tbx2-82/285 directly to a T-Box cis-acting element repressed gene 
expression. Similarly, He et al. (1999) reported that the T-box domain of ET repressed gene 
expression when using a reporter construct that contained two cis-acting elements. However, 
when pB-:Tbx2-82/285 bound to multimerized cis-acting elements (G3PDH-5G-CAT), it 
mildly activated gene expression. Furthermore, pB-Tbx2 was less effective at repressing 
reporter gene activity when multiple cis-acting elements were present (Figure 3). 
Interestingly, Chen et al. (2001) reported that the over-expression of Tbx2 in NIH3T3 cells 
increased and decreased the expression level of numerous genes. While it is not possible to 
determine if Tbx2 is directly responsible for the changes in gene expression observed by 
Chen et al., (2001), in light of our data it is tempting to speculate that Tbx2 may act as a 
repressor or an activator depending on the genomic context. 
3.3 Deletion analysis of the Tbx2 T-box domain. 
The ability of the Tbx2 T-box to transactivate gene expression suggests the presence 
of an interactive domain within the T-box region. To identify the responsible domain, we 
developed a series of T-box deletion constructs (Figure 1). Deletion of the carboxy terminal 
130 amino acids from the T-box domain did not diminish the ability of the Tbx2 T-box to 
transactivate gene expression (Figure 4). These results suggest that the amino terminal end is 
responsible for the increased promoter activity. Based on the crystallographic structure of 
Brachyury, arginine 122 of Tbx2 and arginine 81 of Tbx5 make contact with the major 
groove of DNA (Millier and Herrmann, 1997). Furthermore, Sinha et al. (2000) 
demonstrated that mutation of Arginine 122 abolished the ability of Tbx2 to bind to DNA. 
Interestingly, it was recently reported that Tbx5 interacts with Nkx2-5 (Hiroi et al., 
2001). In contrast to wild-type Tbx2, Tbx5 activated gene expression. Similar to our results 
with the Tbx2 T-box, the interaction between Tbx5 and Nkx2-5 required the amino terminal 
end of the T-box, which suggests the presence of an evolutionary conserved domain within 
the T-box. Thus, this region of the T-box plays an important role in DNA binding and 
interacts with other proteins. This paradigm of DNA binding and protein interaction domain 
has been observed with a number of other transcription factors such as SRF, Nkx2-5, and 
GATA-4 (Chen and Schwartz, 1996; Sepulveda et al., 1998). 
3.4 Identification ofTbx2 repression domains. 
The conflicting results of He et al. (1999), Sinha et al. (2000), and our experiments 
suggest the presence of two or more repression domains within Tbx2. In order to map the 
Tbx2 domains required for repression of gene transcription, a series of Tbx2/GAL4 DNA 
binding domain fusion constructs were generated (Figure 1). Wild-type pB-Tbx2 repressed 
reporter activity (Figure 5). Similarly, pB:Tbx2-515/574 and pB:Tbx2-l/53 repressed gene 
expression (Figure 5). pB:Tbx2-515/574 contained a Tbx2 domain that is almost completely 
conserved in all cloned Tbx2 genes (Data not shown). In addition, this domain is fairly well 
conserved with ET (He et al., 1999). Surprisingly, pB:Tbx2-l/53 was just as effective as 
wild-type Tbx2 at repressing gene expression. He et al. (1999) reported that in cell culture 
experiments this domain was capable of transactivating gene expression. However, this 
region repressed reporter activity in vivo. These results would suggest that the activity of the 
amino terminal domain of Tbx2 is dependent upon the cellular context. The amino terminus 
of Tbx2 is conserved across species (Data not shown) and similar to the amino terminus of 
Tbx3 (Figure 6). However, the amino terminus is not similar to the amino terminus of other 
Tbx family members (Figure 6), suggesting that this domain is truly unique to Tbx2 and 
Tbx3. It is important to note, however, that this similarity may be due purely to the 
evolutionary relatedness of Tbx2 and Tbx3, and not to any functional conservation. In 
contrast, pB:Tbx2-280/528 was transcriptionally inert. This was surprising considering this 
portion of Tbx2 contains three regions that are extremely conserved in all cloned Tbx2 genes 
(Data not shown). However, pB:Tbx2-574/701 repressed promoter activity by approximately 
50% (Figure 5), which suggests that this region may play a role in repression of gene 
expression. This domain contained two domains that are conserved across species (Data not 
shown). 
Our data does not allow us to define the molecular mechanism whereby Tbx2 
represses gene expression. Because of their widespread participation in transcriptional 
repression, it is tempting to speculate that Tbx2 repression may involve either the 
Groucho/TLE family (see review by Chen and Courey, 2000) or the histone deacetylase 
family (see reviews by Ayer, 1999; Ng and Bird, 2000). However, neither of the two 
identified repression domains within Tbx2 contains a WRPW or eh-1 motif, which are each 
necessary and sufficient for the binding of Groucho proteins (Chen and Courey, 2000; 
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Kobayashi et al., 2001), suggesting that the Groucho/TLE family may not be involved in 
Tbx2 mediated transcription repression. 
4. Conclusions 
(1) Deletion analysis of Tbx2 suggests the presence of a novel amino terminal 
transcription repression domain. 
(2) Promoter context alters the ability of the Tbx2 T-box to regulate gene transcription. 
In the presence of a single cis-acting element the T-box represses gene expression. In 
contrast, the T-box activates promoter activity of a reporter gene that contains five 
multimerized cis-acting elements. 
(3) The amino terminal end of the T-box is responsible for the ability of the T-box to 
regulate promoter activity. 
(4) Tbx2 contains two separate transcription repression domains. The amino terminal 
domain is located between amino acids 1 and 53; while, the carboxy terminal domain 
is located between amino acids 529 and 573. 
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Figure 1. Tbx2 constructs. Constructs are named according to the last amino acid residue 
present. In cases of amino-terminal deletions the first amino acid residue present is also 
included. Fusion constructs in pBind are preceded by pB. The T-box domain is represented 
by while [HI represents the GAL4 fusion protein which includes the DNA binding 
domain. 
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Figure 2. Mapping the transcriptional repression domain of Tbx2. C3H10T1/2 cells were 
transacted and analyzed for CAT activity as described in section 2.3. The bar diagram 
shows mean normalized CAT activity ± standard error for G3PDH-LaBS-CAT (1 |ag) in the 
presence of 200 ng of each effecter construct. The expression of wild-type and deletion Tbx2 
did not effect G3PDH-CAT activity (data not shown). Each construct was tested in duplicate 
in four independent experiments. Differing superscripts reflect statistical differences between 
treatments P<0.05. 
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Figure 3. Transcriptional regulation by the Tbx2 T-box is dependent of promoter context. 
C3H10T1/2 cells were transfected and analyzed for CAT activity as described in section 2.3. 
The bar diagram shows the mean normalized CAT activity ± standard error for G3PDH-
LaBS-CAT, which contains a single Tbx cis-acting element, G3PPDH-1 GAL-CAT and -
5GAL-CAT, which contain 1 and 5 GAL4 cis-acting elements, respectively (1 pg), in the 
presence of 200 ng of pB-Tbx2, which contains full-length Tbx2 fused in-frame with GAL4 
DNA binding domain. Each construct was tested in duplicate in three independent 
experiments. Differing superscripts within individual reporter construct represent statistical 
differences between treatments P<0.05. 
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» 2.5 
pBind pB-Tbx2 pB:Tbx2- pB:Tbx2- pB:Tbx2- pB:Tbx2-
82/155 82/224 82/246 82/285 
Figure 4. Deletion analysis of the Tbx2 T-box. C3H10T1/2 cells were transacted and 
analyzed for CAT activity as described in section 2.3. The bar diagram shows the mean 
normalized CAT activity ± standard error for G3PPDH-5GAL-CAT, which contains 5 GAL4 
cis-acting elements (1 pg), in the presence of 200 ng of effecter construct. Each construct 
was tested in duplicate in three independent experiments. Differing superscripts reflect 
statistical differences between treatments P<0.05. 
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« 0.6 
& 0.4 
pBind pB:Tbx2 pB:Tbx2- pB:Tbx2- pB:Tbx2- pB:Tbx2-
515/574 1/53 280/528 574/701 
Figure 5. Mapping the transcriptional repression domain of Tbx2. C3H10T1/2 cells were 
transfected and analyzed for CAT activity as described in section 2.3. The bar diagram 
shows the mean normalized CAT activity ± standard error for G3PDH-5 GAL-CAT (1 pg) in 
the presence of 200 ng of each effecter construct. The expression of wild-type and deletion 
Tbx2 did not affect G3PDH-CAT activity (data not shown). Each construct was tested in 
duplicate in two independent experiments. Differing superscripts reflect statistical 
differences between treatments P<0.05. 
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(A) 
mTbx2 1 --M0YHP§|}lAPRPADBpM§BlL^AQPBEjMLALgPGALBSPLBSBGLAGA|^^Q 
mTbx6 1 M^PREffYPSLGBWRlJBHPOPlADlTFfftLTliBYBYpiLDTSKT.DCF 49 
(B) 
hTbx2 1 MAYHPFHAPRPADFPMSAFLAAAQPSFFPALALPP GALAKPLPDPGLAGAAAAAA 
hTbx3 MSLSMRDPVIPGTS LPH-AP- -A V-G H--P T N--A-LS-- --L-KPI 
Figure 6. (A) Amino acid sequence comparison of the amino terminus of murine Tbx 1, 2, 5, 
and 6 proteins. The identity of residues is ~21% between mTbx2 and mTbxl, ~10% between 
mTbx2 and mTbx5, and ~8% between mTbx2 and mTbx6. Identical amino acids are 
indicated in reverse type. Conserved changes are indicated in gray reverse type. (B) Amino 
acid sequence comparison of the amino terminus of human Tbx2 and Tbx3. TBX3 amino 
acids that are identical to TBX2 are indicated as dashes. Gaps are indicated by blank space. 
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5' repression 
domain 
T-box 
domain 
3' repression 
domain 
H iWil I::;!;:;! 
Conserved regions within cloned Tbx2 with no known function 
Figure 7. Identified Tbx2 functional domains. The checkerboard denotes the 5' 
repression domain defined by He et al. (1999) and our results. The layer brick denotes 
the T-box domain, with the slanted layered brick denoting the transcription domain 
within the T-box, our results. The vertical bars denote the 3' repression domain as 
defined by He et al. (1999) and our results. The five stippled boxes denote regions of 
amino acid conservation across species, which do not have any known function. 
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Chapter 3: Identification of proteins 
that interact with Tbx2 
A manuscript to be submitted to BioMed Central: Journal of Biology 
Christian N Paxton1, Mary Sue Mayes 2, James M Reecy3 
Abstract 
Background 
Tbx2 is a potent repressor of gene expression and contains two repression domains. 
Although many targets of Tbx2 have been described in the literature, little is known about 
how Tbx2 regulates their expression. Target specificity and protein function are believed to 
depend on protein-protein interactions, but few protein interactions have been described. To 
address this question, a whole mouse embryonic day 9.5 (e9.5) library was used in a yeast 2-
hybrid screen to identify proteins that interact with Tbx2. 
Results 
Seven proteins that interacted with Tbx2 were identified including: co-activator of activating 
protein and estrogen receptors (Caper-a), ubiquitin specific processing protease 1 (Uspl), 
heterogeneous nuclear ribonucleoprotein HI, ribosomal protein L5, nascent polypeptide-
associated complex alpha, proteasomal subunit (macropain) ATPaseS, and E3 ubiquitin 
ligase HECT domain containing 1. In addition to interaction in the yeast system with the 
amino terminal repression domain of Tbx2, the deubiquitinase Uspl and 
'Primary researcher and principle author 
^Performed all in situ hybridizations 
3Major Professor and corresponding author 
the transcription and splicing cofactor Caper-a were also shown to interact with wild-type 
Tbx2 in a mammalian cell culture system. By deletion mapping of Uspl, Tbx2 was shown to 
interact with the second UCH domain of Uspl, which forms the active site responsible for 
Uspl deubiquitinase activity. The Expression patterns of Uspl and Caper-a in e9.5 embryos 
overlapped with Tbx2. These are areas where Tbx2 could potentially interact with either 
Uspl or Caper-a in vivo. Neither Uspl or Caper-a altered the ability of Tbx2 to regulate 
promoter activity 
Conclusions 
Tbx2 interacts with Caper-a and Uspl in vitro. In addition, there are areas where Caper-a 
and Uspl are co-expressed with Tbx2 in the developing embryo and (for Uspl) in the adult 
and as such indicate sites where Tbx2 could interact with Caper-a and Uspl in vivo. These 
interactions may not play a role in transcriptional regulation, which is reported to be the 
primary function of Tbx2. Although biological functions for these interactions have not yet 
been assigned, there is some evidence that Uspl may interact with Tbx2 to deubiquitinate it. 
Background 
Tbx2 belongs to a novel family of transcription factors that contain a highly 
conserved DNA binding domain, known as the T-box (Bollag et al., 1994). All T-box 
proteins examined to date are capable of binding the consensus sequence TCACACCT, 
which is known as the T half-site (Tada and Smith, 2001; Naiche et al., 2005). Little protein 
conservation exists outside of the T-box, which indicates that individual T-box proteins may 
have specific functional domains encoded in these areas. Indeed, unique transactivation 
domains have been characterized in the carboxy-terminal regions of some of these proteins 
such as Brachyury (Kispert et al., 1995), Tbx5 (Zaragoza et al., 2004), and Tbx20 (Stennard 
et al., 2003), while repression domains have been identified in Tbx2, Tbx3, ET and Tbx20 
(Sinha et al., 2000; He et al., 1999; Paxton et al., 2002; Stennard et al., 2003). 
Expression patterns of T-box genes are very dynamic, yet often overlap, during 
embryo genesis. Because T-box proteins can bind the same consensus sequence, it is 
believed that target specificity results from specific protein-protein interactions (reviews by 
Tada and Smith, 2001; Showell et al., 2004). Surprisingly, very few protein interactions 
have been identified for T-box proteins. TBX5, for example, has been reported to interact 
with the transcription factors Nkx2.5 (Hiroi et al., 2001) and GAT A4 (Garg et al., 2004) to 
synergistically activate atrial natriuretic factor (ANF) gene transcription. Tbx2 was also 
shown to cooperatively interact with Nkx2.5 to regulate transcription of ANF, but in this case 
ANF was repressed, not activated (Habets et al, 2002). Furthermore, Tbx2 was recently 
shown to interact with Tbx5 (Barron et al., 2005) and with the co-repressor histone 
deacetylase 1 (HDAC1) (Vance et al, 2005). Identification of additional proteins that interact 
with individual T-box proteins may offer a means to better understand T-box protein 
functions and specificity. 
Tbx2 is a potent repressor of gene expression that contains two repression domains, 
one in the carboxy-terminal portion of the protein (Habets et al., 2002; Sinha et al., 2000), 
and one at the amino-terminus (Paxton et al., 2002). Recently, HDAC1 was reported to 
interact with the carboxy-terminal repression domain of Tbx2, only the third protein reported 
to interact with Tbx2. Furthermore, this interaction was sufficient for repression of gene 
activity (Vance et al., 2005). Although this potential mechanism of action was proposed for 
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the carboxy-terminal repression domain, a mechanism of repression via the amino-terminal 
repression domain is unknown. The objective of this study was to identify proteins that 
could interact with Tbx2. 
Results and discussion 
Protein-protein interactions 
To identify interactive proteins in this study, a cytoplasmic yeast 2-hybrid system was 
used. This system took advantage of a temperature sensitive strain of Saccharomyces 
cerevisiae (cdc25H) and was previously described in detail by Aronheim and colleagues 
(1997). In short, the cdc25H strain could grow at 25° C, but not at the restrictive temperature 
of 37° C due to failure in the activation of the RAS growth pathway. The human homologue 
of CDC25, the guananyl nucleotide exchange factor SOS allowed for compensation of the 
temperature sensitive mutation when brought into proximity with RAS. The coding 
sequence for the target protein(s), fused with a myristylation signal, was under the direction 
of a galactose-induced promoter and therefore, required the presence of galactose for 
production of the target fusion protein. The presence of the myristylation signal directed the 
translocation of the target protein to the inside of the cellular membrane, where inactive RAS 
was located. A protein-protein interaction between the target and the bait therefore, 
transported SOS to the cell membrane, into proximity with RAS. Activation of RAS was 
induced and resulted in subsequent growth of cdc25H at 37° C on selective galactose media. 
In order to identify proteins that could interact with Tbx2, the SOS protein was fused 
with either the amino-terminal repression domain (SOS:Tbx2-Nrep), the T-box domain 
(SOS:Tbx2-82/285) or the carboxy terminal repression domain (SOS:Tbx2-515/574) (Figure 
3). Each SOS fusion was used as bait to screen an e9.5 whole mouse library. For 
SOS:Tbx2-Nrep, approximately 300,000 colonies were screened for their ability to grow at 
the selective temperature of 37° C on media that contained galactose, indicative of a putative 
positive interaction. One hundred forty-seven colonies demonstrated a putative positive 
interaction, and were further analyzed for galactosc-dependent growth at the selective 
temperature of 37° C. Colonies that grew at the selective temperature on glucose media were 
considered false positives and removed from the study, which narrowed the selection to 46 
colonies. Plasmid DNA was isolated from the forty-six colonies and subjected to restriction 
endonuclease digestion analysis, which identified nine groups of clones that demonstrated 
non-redundant restriction patterns. One representative clone was selected from each group 
and co-transformed into cdc25H with SOS:Tbx2-Nrep expression vector, to confirm 
interaction. These nine clones were then sequenced and analyzed for gene identity by Blast 
analysis (Altschul et al., 1990). Two of these clones contained coding sequences for RAS 
and RAS-like proteins. Fusion of RAS to a myristylation signal has been shown to activate 
the RAS pathway (Buss et al., 1989). Furthermore, both of these constructs induced growth 
at 37° C in the absence of bait protein, which indicated that an interaction was not required 
for growth. Therefore, RAS constructs were eliminated from the study as false positives. 
Of the seven clones that remained, six unique gene products were identified. Two of 
the seven clones contained overlapping regions for the coding sequence of residues 318-530 
of murine Caper-a. The six proteins identified were as follows: co-activator of activating 
protein and estrogen receptors (Caper-a), ubiquitin specific processing protease 1 (Uspl), 
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heterogeneous nuclear ribonucleoprotein HI, ribosomal protein L5, nascent polypeptide-
associated complex alpha, and proteasomal subunit (macropain) ATPase3 (Table la). 
Approximately 200,000 colonies were screened with SOS:Tbx2-82/285, thirty-six of 
which demonstrated galactose-dependent growth. Based on restriction endonuclease 
digestion analysis seven unique clones were sequenced. Analysis of the sequences identified 
the gene products as Uspl (which also interacted with the amino-terminal repression 
domain), three RAS-related proteins (discarded as false positives), and three hypothetical 
proteins. Two of the three hypothetical proteins were recently identified as E3 ubiquitin 
protein ligase, HECT domain containing, 1 (Eddl) (Table lb). In two independent screens, 
SOS:Tbx2-515/574 was used to analyze approximately 600,000 colonies for selective 
growth. A total of four hundred thirty colonies were selected and analyzed for galactose-
dependent growth to identify putative positive interactions. All colonies demonstrated non­
selective growth at 37° C, indicative of false positives. The identification of such a large 
number of false positives with SOS:Tbx2-515/574 was unexpected. It is unknown why this 
fragment of Tbx2 resulted in the identification of only false positive clones, most of which 
did not have homology to RAS family members. As a result, this study focused on protein 
interactions with the amino-terminal repression domain. 
A literature search was performed for the six proteins that interacted with the amino-
terminal repression domain. Based on that search, Caper-a and Uspl were selected for 
further investigation because of potential involvement in the regulation of transcription. 
Caper-a had been shown to act as a co-activator of gene transcription, induced by the 
transcription factor AP-1 and estrogen receptors (Jung et al., 2002). The deubiquitinase Uspl 
was selected because of a growing body of literature that implicated deubiquitination in 
transcriptional regulation. For example, the deubiquitinase Ubp8 was shown to 
deubiquitinate histone 2B, which resulted in subsequent gene activation (Daniel et al, 2004). 
Therefore, the interactions between Tbx2 and both Caper-a and Uspl were further 
characterized in this study. 
In addition to interaction in yeast, full-length Uspl and Caper-a were tested for their 
ability to interact with wild-type Tbx2 in a mammalian cell culture system. Cos? cells were 
co-transfected with pcDNA3:Tbx2 or empty pcDNA3 vector and either pHA:Uspl, 
pHA:Caper-a or pCMV:HA. Immunoprecipitation analysis was performed with either an 
antibody against the HA epitope, or anti-serum against Tbx2. Proteins were size separated 
by denaturing polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose 
membrane, and probed with anti-serum against Tbx2. Tbx2 protein was undetected in cell 
lysates transacted with pHA:Uspl in combination with pcDNA3 (Figure 1; lane 5). In 
contrast, from cells trans fected with pcDNA3:Tbx2, Tbx2 protein immunoprecipitated with 
Tbx2 anti-sera (Figure 1; lane 2). Tbx2 was also shown to co-immunoprecipitate with 
HA:Uspl (Figure 1; lane 4) and, to a lesser degree, HA:Caper-a (Figure 1; lane 1), but not 
with lysates that expressed empty HA tag alone (Figure 1; lane 3). These results 
demonstrated that full-length Tbx2 interacted with full-length Uspl and Caper-a. 
Furthermore, these interactions occurred in a mammalian cell culture system. It was 
interesting to note that Tbx2 protein isolated from these Cos? cells ran at about 110 kD, as 
compared to estimated size of 74 kD. It is possible that Tbx2 was post-translationally 
modified, which could account for the difference in size. 
Deletion mapping of Caper-a and Uspl domains that interact with Tbx2 
To further delineate the regions of Uspl and Caper-a that interacted with Tbx2-Nrep, 
deletion constructs of Uspl and Caper-a were made and fused with a myristylation signal. 
The deletion constructs were then analyzed for their ability to interact with SOS:Tbx2-Nrep 
in the cytoplasmic yeast 2-hybrid system previously utilized. Interactions of the protein 
fragments were indicated by the ability of the cdc25H yeast strain to grow on galactose 
media at the selective temperature of 37° C. Selective growth of cdc25H was observed for 
colonies that had been co-transformed with SOS:Tbx2-Nrep expression vector and either 
Uspl:345-785, Uspl:345-765 or Uspl:345-470 expression vectors, but not in colonies that 
contained Uspl:345-414, Uspl:384-449 or Uspl:463-615 expression vectors (Figure 2). 
The region of Uspl that interacted with Tbx2 was narrowed to residues 449-463 of 
Uspl (Figure 2). These residues lie within the second of two ubiquitin carboxy-terminal 
hydrolase (UCH) domains. The two UCH domains are characteristic of the deubiquitinase 
(DUB) family to which Uspl belongs (review by D'Andrea and Pellman, 1998). These two 
domains have been shown to fold together in the tertiary structure of DUB proteins to form 
the active site responsible for deubiquitinase activity (Hu et al., 2002). The ability of Tbx2 to 
interact within a UCH domain, therefore, indicates that Uspl may function to deubiquitinate 
Tbx2. Alternatively, Tbx2 may interact with Uspl to block the active site of Uspl and 
inhibit its ability to deubiquitinate other substrates. 
Interestingly, a Uspl cDNA was also identified in an initial screen of the e9.5 whole 
mouse library with an SOS fusion construct that contained the T-box domain as bait 
(SOS:Tbx2-82/285) (Table lb). Additional analysis of Uspl subsequently confirmed the 
ability of Uspl to interact with the T-box domain of Tbx2. The SOS:Tbx2-Nrep and the 
SOS:Tbx2-82/285 fusion constructs contained six overlapping residues, Tbx2 82-87 
(LKSLEP) (Figure 3). The ability of Uspl to interact with both Tbx2-Nrep and Tbx2-82/258 
indicated that Uspl may have interacted with these six residues of Tbx2. The SOS:Tbx2-
1/53 bait construct was unable to interact with either Uspl:345-765 or Uspl:345-470, 
constructs that interacted with Tbx2-Nrep. This construct differed from SOS:Tbx2-Nrep by 
deletion of residues 78-87, which contained the region that overlapped with SOS:Tbx2-
82/285. Therefore, it appears that residues 82-87 are required for the interaction between 
Tbx2 and Uspl. 
Protein ubiquitination involves the formation of an isopeptide bond between the 
carboxy group of ubiquitin and a free amine group of either the amino-terminal residue of a 
protein or a lysine side chain. The presence of lysine 83 provides a potential site for 
ubiquitination of Tbx2. Furthermore, in the initial library screen with SOS:Tbx2-82/285 as 
bait, two individual clones were recently identified as partial coding sequences for an E3 
ubiquitin ligase protein, Eddl (Table lb). Taken together, these data further indicate the 
possibility that a ubiquitin modification of Tbx2 may be regulated by Uspl. However, to 
date we have been unable to observe endogenous Tbx2 in a ubiquitinated form. 
For the Caper-a deletion constructs, only colonies that co-expressed SOS:Tbx2-Nrep 
and CPR:318-530 demonstrated growth on galactose media at the selective temperature. 
Colonies that co-expressed SOS:Tbx2-Nrep with either CPR:318-392, CPR:318-376, 
CPR:318-356, CPR:318-415, CPR:392-517, CPR:392-483, CPR:392-450 or CPR:392-417 
were unable to grow at 37° C (Figure 4). These results indicated that the carboxy-terminal 
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fourteen Caper-a residues, 518-530, were necessary for the interaction of Caper-a with Tbx2-
Nrep. 
Investigation into potential gene regulation via Uspl and Tbx2 
Histone modifications, such as those performed by histone deacetylases, have been 
shown to regulate gene activity (review by Kuo and Allis, 1998). Recently, histone 
ubiquitination has received a great deal of attention in the area of transcriptional regulation. 
For example, Pham and Sauer (2000) demonstrated that TAFII250 could ubiquitinate 
histone-1 and subsequently activate gene transcription. Both ubiquitination and de-
ubiquitination of histone tails have been shown to regulate gene expression (review by 
Zhang, 2003). Because of the role of Tbx2 as a transcription factor, and the growing body of 
literature that implicated DUB proteins in gene regulation, it was hypothesized that Uspl 
could mediate the ability of Tbx2 to regulate gene transcription. 
To determine if Uspl could directly regulate transcription, it was fused with Gal4-
DBD and analyzed for its ability to regulate the G3PDH-5Gal-Luc reporter gene which 
contained five Gal4 cw-acting elements. Cos7 cells were co-transfected with reporter gene 
construct and increased amounts of Gal4:Uspl expression vector. Cells were harvested 48 
hours after transaction and assayed for luciferase activity. As compared to the control, 
Gal4:Uspl did not significantly alter expression of the reporter gene (Figure 5A). 
Subsequently, pB:Uspl and pcDNA3:Tbx2 were co-transfected into Cos7 cells to determine 
if Tbx2 and Uspl could cooperatively influence gene expression. Interestingly, a significant 
increase in promoter activity was observed when Gal4:Uspl was co-expressed with 
progressively increased amounts of wild-type Tbx2 (Figure 5B). 
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Although Tbx2 has been described as a strong repressor of transcription, there is 
evidence that Tbx2 may also play a role in gene activation. In addition to the two described 
repressor domains, a small domain capable of activation was identified in the amino-terminus 
of the T-box domain in Tbx2 (Paxton et al., 2002). Recently Barron and colleagues (2004) 
demonstrated that Tbx2 could activate the serum response factor (SRF) gene, either alone or 
synergistically with the histone acetyltransferase TIP60. Since Tbx2 cooperatively activated 
transcription with Gal4:Uspl, it was hypothesized that Uspl could reverse Tbx2-induced 
repression, to act as a potential transcriptional switch between Tbx2-induced repression and 
activation. Uspl was over-expressed to determine if it could reverse promoter repression by 
Tbx2. Cos7 cells were co-transfected with G3PDH-5Gal-Luc reporter, pB:Tbx2 and 
increased amounts of pcDNA3:Uspl. The ability of Tbx2 to repress transcription of the 
reporter gene was unaffected at all levels of Uspl over-expression examined. Therefore, it 
was concluded that over-expression of Uspl was unable to reverse Gal4:Tbx2 induced 
repression (Figure 5C). 
It is unclear why Tbx2 and Gal4:Uspl together activated transcription, while Uspl 
was unable to affect Gal4:Tbx2 induced repression. One possibility is that over-expression 
of wild-type Tbx2 may have interacted with endogenous repressor proteins, and acted as a 
sink to remove them from the promoter. Although it was not significant, Gal4:Uspl alone 
demonstrated a tendency towards reporter gene activation. The loss of repressor proteins 
from the promoter could then have resulted in an increased ability of Gal4:Uspl to activate 
transcription, which would account for the significant increase observed in reporter gene 
activity. Alternatively, the increased activity may have resulted from the ability of Tbx2 to 
activate transcription. The T-box domain, when fused with Gal4 DNA binding domain, was 
previously shown to repress gene activity from a single T half-site, yet activate promoter 
activity from multimerized Gal4 czs-acting elements (Paxton et al, 2002). Furthermore, 
Barron and colleagues (2004) attributed the Tbx2-induced activation of SRF to the presence 
of multimerized T half-sites found in the 3 ' untranslated region of the gene. It is possible in 
this situation, where Gal4:Uspl and Tbx2 cooperatively increased reporter gene activity, that 
the interaction of Gal4:Uspl merely recruited Tbx2 to the promoter. Multiple Gal4:Uspl 
fusion proteins bound to the promoter would have provided sites for multiple Tbx2 proteins 
to interact, albeit indirectly, with the promoter. Such a scenario would have in essence 
simulated multimerized T-box binding sites. In contrast, full-length Tbx2 fused to Gal4-
DBD repressed activity from multiple Gal4 elements. Presumably, the fusion of full-length 
Tbx2 with the Gal4-DBD prevented a conformational change in Tbx2 required for gene 
activation to occur. 
Investigation into potential gene regulation via Caper-a and Tbx2 
Caper-a has been shown to enhance the ability of AP-1 and some steroid receptors to 
activate gene expression (Jung et al., 2002; Dowhan et al., 2005). To determine if Caper-a 
could directly regulate transcription, it was fused with Gal4-DBD and analyzed for its ability 
to regulate G3PDH-5Gal-luc reporter gene activity. Transient transactions were performed 
in two independent cell lines, Cos? and C3H/10T1/2. Cells were transfected with either 
pBind vector, as control, or pB:Caper-a. As compared to the control, Gal4:Caper-a was 
unable to alter promoter activity in a Cos? cell-line (data not shown). Similar results were 
described by Jung and colleagues (2002) in a CV-1 cell line, in which they reported that 
expression of full-length Caper-a fused to a Gal4-DBD was transcriptionally inactive. In 
contrast, Gal4:Caper-a repressed promoter activity in C3H/10T1/2 cells (Figure 6A). The 
difference in Gal4: Caper-a function observed between cell lines may result from different 
protein profiles present in individual cell lines. Cos? cells were derived from a CV-1 cell 
line (Gluzman, 1981), which indicates that they have similar cellular profiles. Furthermore, 
CV-1 and Cos? cells originated from adult African green monkey kidney (Jensen et al., 
1964). In contrast, C3H/10T1/2 cells were originally isolated from a mouse embryo 
(Reznikoff et al., 1973). Therefore, Cos? cells and C3H/10T1/2 cells vary in both origin of 
species and stage of development. These differences would indicate that their cellular 
profiles could vary as well. Proteins that exhibit different functions in different cell lines are 
not uncommon. Estrogen receptor alpha, for example, has been shown to repress NFKB 
promoter in HeLa cells, but not HEK293 cells (Cerillo et al., 1998). 
The ability of full-length Caper-a to repress promoter activity in C3H/10T1/2 cells 
indicated a potentially novel role for Caper-a. Furthermore, endogenous Caper-a message 
was detected in C3H/10T1/2 cells by reverse transcription (RT)-PCR analysis (data not 
shown). Therefore, the hypothesis that Caper-a acted as a co-repressor to mediate repression 
induced by the amino-terminal repression domain of Tbx2 (Tbx2-Nrep) was put forth. This 
hypothesis was tested by RNA interference analysis of Caper-a. 
Two Caper-a siRNA constructs (designated Caper-1 and Caper-2 respectively) were 
obtained and initially tested for their ability to abrogate repression induced by the 
Gal4:Caper-a fusion protein in C3H/10T1/2 cells. Cells were transiently co-transfected with 
100 ng of either pB: Caper-a or pBind, as control, along with 800 ng siRNA expression 
construct. The siRNA treatments included either 1) pGFP-siRNA, as control, 2) pCaper-1, 3) 
pCaper-2 or 4) a combination of 400 ng each of pCaper-1 and pCaper-2 siRNA constructs. 
The last treatment was included to investigate the possibility that a combination of the two 
siRNA constructs against Caper-a could more effectively knock-down Caper-a than either 
siRNA construct alone. 
In the presence of GFP-siRNA, Gal4:Caper-a repressed promoter activity to 
approximately 60% of the activity observed by the Gal4-DBD control (Figure 6B). 
Gal4:Caper-a repressed promoter activity just as effectively in the presence of Caper-1 
siRNA, which indicated that Caper-1 had no effect on Gal4:Caper-a function. In contrast, 
Caper-2 siRNA significantly abrogated the ability of Gal4:Caper-a to repress promoter 
activity. With the expression of Caper-2, promoter activity was restored to approximately 
87% of the activity observed in the Gal4-DBD control (p<0.01). A combination of Caper-1 
and Caper-2 also abrogated repression (p<0.01), but to a lesser degree. Promoter activity in 
the last case was restored to approximately 71% compared to the activity observed in the 
Gal4-DBD control (Figure 6B). Therefore, Caper-2 siRNA, but not Caper-1 siRNA, could 
effectively knock down Caper-a. 
Caper-2 siRNA was next analyzed for its ability to abrogate Gal4:Tbx2-Nrep 
repression, to test the hypothesis that Caper-a was required for repression by Tbx2-Nrep. 
C3H/10T1/2 cells were co-transfected with 100 ng of either pB:Tbx2-Nrep or pBind as 
control, and either pGFP-siRNA control or pCaper-2 siRNA. Gal4:Tbx2-Nrep repressed 
promoter activity as effectively in the presence of Caper-2 siRNA as it did in the presence of 
GFP-siRNA control (Figure 6C). Based on these assays, Caper-a did not appear to be 
necessary for repression induced by Gal4:Tbx2-Nrep. 
The significance of Caper-a and Tbx2 interaction may have functional consequences 
at a level other than transcriptional regulation. In addition to the ability of Caper-a to co-
activate promoter activity, Dowhan and colleagues (2005) demonstrated that Caper-a could 
also regulate the proportion of transcribed RNAs from alternatively spliced genes both in 
vivo and in vitro. Furthermore, the domains responsible for co-activation and splicing 
functions were shown to be independent of each other (Dowhan et al., 2005). It is possible 
that the interaction of Tbx2 and Caper-a may indicate a potential role for Tbx2 in alternative 
splicing. A few genes regulated by Tbx2 have also had alternative splice variants identified. 
Two examples include connexin (Cx)40 (Dupays et al., 2003; Anderson et al., 2005) and 
Cx43 (Pfeifer et al., 2004). In further support of this potential role, three of the six proteins 
that interacted with Tbx2 in the yeast 2-hybrid study presented here were also identified in a 
purified splicesome complex (Rappsilber et al, 2002). 
Tbx2 is co-expressed with both Uspl and Caper-a in vivo 
The absence of a role in transcription, based on the assays used here, does not rule out 
the possibility of a biological role for these interactions in other cellular processes. 
Additional evidence to indicate that these proteins interact includes areas of co-expression. 
At e9.5, Tbx2 expression studies have focused on Tbx2 mRNA expression patterns in the 
heart. At this stage in the heart Tbx2 mRNA expression has been described in the 
atrioventricular canal, the in-flow tract and the out-flow tract (Habets et al., 2002; Yamada et 
al., 2000). In addition to the heart, Tbx2 mRNA expression was also reported in the otic 
vesicle, optic vesicle, somites, forelimb, branchial arches and head mesenchyme overlying 
the forebrain (Bollag et al., 1994; Harrelson et al., 2004). Therefore, it was hypothesized that 
Caper-a and Uspl was also expressed in some of the tissues where Tbx2 expression had been 
reported. 
To determine if Tbx2 was co-expressed with either Caper-a or Uspl, mRNA 
expression patterns of Caper-a, Uspl and Tbx2 were visualized by in situ hybridization 
analysis. In agreement with previous reports, Tbx2 mRNA was expressed in the heart, 
branchial arches, optic and otic vesicles, and in the mesenchyme overlying the forebrain 
(Figure 7A). Although Tbx2 mRNA was not detected in the somites, or forelimb at this stage 
of development in this study, expression was visualized in these regions at el 0.5 (Figure 6B). 
In addition, at el 0.5 Tbx2 was also observed in the anterior and posterior regions of the hind-
limb (Figure 7B). 
The expression patterns of Uspl and Caper-a were visualized at e9.5. At this stage of 
development, murine Uspl mRNA expression was concentrated in the developing spine, 
branchial arches, optic vesicle, and otic vesicle (Figure 7C). Interestingly, the areas that 
demonstrated expression of. Uspl were tissues where Tbx2 expression was also observed, 
specifically, the branchial arches, and in the optic and otic vesicles. In contrast to the defined 
patterns of Uspl and Tbx2 expression, Caper-a demonstrated a very broad range of 
expression throughout the e9.5 murine embryo. Caper-a mRNA expression was actually 
observed throughout most of the embryo, the one exception was a lack of Caper-a message 
in the majority of the heart, particularly in the ventricles (Figure 7D). Specific areas where 
Tbx2 and Caper-a co-expression was detected include the branchial arches, optic and otic 
vesicles and the mesenchyme overlying the forebrain (Figure 7B & 7D). These patterns of 
co-expression indicate that there are tissues where Tbx2 and either Uspl or Caper-a could 
potentially interact in vivo during embryonic development. 
In addition to embryonic expression patterns, adult murine tissues that expressed 
Uspl were identified by RT-PCR. Uspl was detected in the small intestine, spleen, liver, 
lung, kidney, heart, adipose, and stomach. A small amount of message was observed in the 
brain and skeletal muscle, but none was detected in the skin (Figure 8A). As control, Gapdh 
was RT-PCR amplified from cDNAs of all tissues (Figure SB). Expression of Tbx2 has been 
reported in the adult murine heart, lung, kidney, and ovary (Bollag et al., 1994). Although 
this study did not include the ovary, Uspl expression observed in the heart, lung and kidney 
indicate that there are also adult tissues in which Tbx2 and Uspl are co-expressed. 
Therefore, areas of overlapped expression exist both in the embryo and in the adult where 
Uspl and Tbx2 could potentially interact in vivo. 
Conclusions 
The objective of this study was to identify proteins that could interact with the amino-
terminal repression domain of Tbx2. Six proteins that interacted with this domain were 
identified in a yeast 2-hybrid screen of an embryonic library. Of these six proteins, Caper-a 
and Uspl were also shown to interact in a more native state with full-length Tbx2 from co-
transfected Cos7 cells. 
In an attempt to assign biological roles for the interactions of Tbx2 with either Caper-
a or Uspl, a series of transcriptional assays were employed to determine the extent to which 
these interactions could regulate gene transcription. Co-expression of a Gal4:Uspl fusion 
with wild-type Tbx2 in Cos? cells significantly activated reporter gene activity. However, 
when tested for its ability to alter Gal4:Tbx2 function, the over-expression of Uspl had no 
effect on Tbx2-induced repression. 
Although Caper-a has been described as a co-activator of transcription, the results 
presented here indicate that when targeted directly to the promoter Caper-a could repress 
gene transcription in C3H/10T1/2 cells, yet appeared to be transcriptionally inert in Cos? 
cells. Due to the ability of Gal4:Caper-a to repress transcription in C3H/10T1/2 cells, the 
hypothesis that Caper-a was responsible for repression induced by Gal4:Tbx2-Nrep was 
investigated. Knock-down of Caper-a appeared to have no affect on Gal4:Tbx2-Nrep 
mediated repression, which indicated that Caper-a was not required for Gal4:Tbx2-Nrep 
repression. 
The domains responsible for interaction with Tbx2 were mapped in both Caper-a and 
Uspl. Tbx2 was shown to interact with residues 518-530 of Caper-a. The interaction 
domain of Uspl was mapped to residues 449-463, which lie within UCH domain of Uspl. 
The interaction of Tbx2 within this domain indicates a potential role for deubiquitination of 
Tbx2 by Uspl. Although ubiquitination of Tbx2 has not yet been reported, there is some 
evidence to indicate that a ubiquitinated form of Tbx2 may exist. The presence of a lysine 
residue within Tbx2 amino acids 82-87, which appear to be required for the interaction 
between Tbx2 and Uspl, would provide a potential site for Tbx2 ubiquitination. In addition, 
the identification of Eddl as a potential interactive partner for the T-box domain of Tbx2 
would further indicate that Tbx2 may be ubiquitinated in some manner. The potential for 
Tbx2 ubiquitination would indicate a potential role for Uspl in the deubiquitination of Tbx2. 
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An alternative explanation for the interaction of Tbx2 within the active site of Uspl may be 
to inhibit the function Uspl through the prevention of Uspl binding to other substrates. 
Although the biological significance of these interactions is not yet clear, areas of co-
expression have been identified in the embryo and (for Uspl) in the adult. The similar 
patterns of co-expression for Tbx2 and both Caper-a and Uspl indicate areas where Tbx2 
could potentially interact with these proteins in vivo. 
Methods 
Plasmids and constructs 
For the yeast 2-hybrid screen, the coding sequence for the amino terminal repression 
domain of murine Tbx2 (Tbx2-Nrep) was isolated by restriction endonuclease (RE) digestion 
with Bglll and Xhol and cloned into the BamHI-Sall sites of pSOS vector (Stratagene), in-
frame with the coding sequence of human SOS protein (pSOS:Tbx-Nrep). The Tbx2-Nrep 
constructs contain the coding sequence for Tbx2 residues 1-87, with a deletion that 
corresponds to residues 54-77 (Figure 3). To generate the pSOS:Tbx2-82/285 construct, 
Tbx2-82/285 cDNA was isolated from pB:Tbx2-82/285 (Paxton et al., 2002) by BamHI RE 
digestion and cloned into the BamHI site of pSOS vector. Tbx2-515/574 cDNA was isolated 
by BamHI-NotI RE digestion and cloned into the BamHI-NotI sites of pSOS to make the 
pSOS:Tbx2-515/574 bait construct. The pSOS:Tbx2-l/53 construct was generated by NotI 
RE digestion of pSOS:Tbx2-Nrep, to remove the coding sequence for amino acids 78-87, and 
ligation of the ends. Messenger RNA was isolated from e9.5 embryos with the Micro-
fastTrack™ kit (Invitrogen) according to the manufacturer's protocol. The mRNA was 
shipped to Stratagene for construction of the library. In short, the library contained cDNAs 
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generated by reverse transcription of the e9.5 murine mRNA and subsequently cloned into 
the EcoRI-XhoI sites of the pMyr vector. 
Deletion constructs were made by RE digestion of the Caper-a cDNA with Xhol and: 
BsaHI (CPR 318-415), PvuII (CPR 318-392), EcoRI (CPR 318-376), and BspMI (CPR 318-
356). Additional deletion constructs of Caper-a were generated by PCR amplification with 
the forward primer 1275f (5'-CGG AAT TCA TTT GAC AGT G-3') in conjunction with the 
following reverse primers: CPR392-417 primer 1517r (5'-GTC TCG AGA CGC AGC TGC 
AGC TAA AC-3'), CPR392-450 primer 1617r (5'-CTC GAG TGA CAT CAT CTT TAA 
TCT CTC-3'), CPR392-483 primer 1717r (5'-ACT CGA GCC GCA GCA ATA GAT GGG 
CA-3'), and CPR392-517 1817r (5'-CTC GAG ATC AGG AAA GAG GTT GTG G-3'). 
Amplified Caper-a cDNA fragments were cloned into pGEM-T Easy (Promega) and then 
subcloned into the EcoRI-XhoI sites in the pMyr vector (Stratagene) in-frame with the 
myristylation sequence. 
Two Uspl deletion constructs were made by RE digestion of the Uspl cDNA with 
Xhol and either SacI (Usp 1:345-465) or EcoRI (Uspl:345-764). The remaining Uspl 
deletion constructs were PCR amplified with the corresponding primers as follows: 
Uspl:345-414 primer Usp345f (5'-GAA TTC TCC ACT AAG CAA CCC AGC AT-3') and 
primer Usp414r (5'-CTC GAG TTT CCG GAC TTG GCT TCA CT-3'), Uspl:384-449 
primer Usp384f (5'-GAA TTC AAG TAC GGA AGT GAC CAC AC-3') and primer 
Usp449r (5'-CTC GAG TCT TCT TTC TGT TAA GCT TT-3'), and Uspl:463-615 primer 
N104Sacl (5'-GAA TTC CAT GAG CTT TCC AAG GTC GAG GAG A-3') and primer 
N104Sac2 (5'-CTC GAG TCA ACC ACA AAA TTC CCC TCA TCG-3') (Integrated DNA 
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Technologies). The PCR products were ligated into pGEM-T Easy (Promega) and 
subsequently cloned into the EcoRI-XhoI sites ofpMyr (Stratagene, La Jolla, California). 
To generate the G3PDH-5Gal-Luc reporter construct, G3PDH-5Gal promoter was 
isolated from G3PDH-5 Gal-C AT (Paxton et al., 2002) by Sail RE digestion and subcloned 
into the Sail site of pBlueScript II SK+ (Stratagene). The promoter was subsequently 
isolated by KpnI-SacI RE digestion and cloned into the KpnI-SacI sites of pGL3-Basic 
(Promega) to drive expression of the luciferase reporter gene. 
Wild-type Tbx2 expression vector, pcDNA3:Tbx2, was provided by Dr. Roni Bollag 
(Chen et al., 2001), and a full-length Caper-a expression vector, pcDN A3 : Caper-a, was 
provided by Dr. Jae Woon Lee (Jung et al., 2002). A full-length Uspl clone was obtained 
from American type culture collection (ATCC; clone Id# 7490242) and sequenced to confirm 
gene identity. Full length Uspl cDNA was shuttled through pBind (Promega; see pB:Uspl 
construction below) and sub-cloned into the BamHI-NotI sites of pcDNA3 (Invitrogen) as a 
BamHI-NotI fragment to make the mammalian Uspl expression vector pcDNA3:Uspl 
To generate pB: Caper-a, which encodes wild-type Caper-a fused with Gal4-DNA 
binding domain (DBD), Caper-a cDNA was isolated from pcDNA3 :Caper-a by Avrll-Xbal 
RE digestion, and cloned into pBind (Promega) that had been linearized with Xbal. 
Generation of the pB:Tbx2 and pB:Tbx2-Nrep constructs, which encode either wild-type 
Tbx2 or the n-terminal repression domain of Tbx2 fused with the Gal4-DBD respectively, 
was previously described (Paxton et al., 2002). To generate the pB:Uspl construct, full-
length Uspl cDNA was PCR amplified from ATCC clone #7490242 with the Uspl start (5'-
ACT CGA GAG AAA ATG CCT GGC-3') and Uspl-2F (5'-ACT GAT AAT ATT TTG 
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ATT TAT ATG-3') primers and Platinum® Taq DNA polymerase (Invitrogen) as described 
by the manufacturer. The PCR product was ligated into pGEM-T Easy (Promega), and the 
full length Uspl cDNA was then sub-cloned into the Sall-Xbal sites of pBind (Promega) as 
an Xhol-Spel fragment, in frame with the coding sequence for Gal4-DBD. 
The pHA:Caper-a and pHA:Uspl constructs were generated by isolation of full-
length Caper-a or Uspl cDNAs, from pB:Caper-a and pB:Uspl respectively, by BamHI-NotI 
RE digestion, and subsequently cloned into the Bglll-NotI sites of pCMV:HA (Clontech). 
The Caper-1, Caper-2 and GFP siRNA expression constructs were kindly provided by Dr. 
Dennis Dowhan. 
Library screening and deletion studies 
The e9.5 whole mouse library was screened with the CytoTrap™ yeast 2-hybrid kit 
according to the manufacturer's protocol (Stratagene). Briefly, the cdc25H-a temperature 
sensitive yeast strain was co-transformed with pSOS:Tbx2-Nrep and the e9.5 whole mouse 
cDNA library (Stratagene). Transformants (~3 x 105) were grown on glucose media at 25° C 
for 2-3 days then replicated to plates that contained selective galactose media and incubated 
at 37° C for 4-6 days. Colonies were tested for galactose dependent growth at 37° C, 
indicative of putative interactions. In contrast, colonies that grew at 37° C on plates that 
contained glucose media were discarded as false positives. Plasmid DNA was isolated from 
each of the putative positives, and subjected to RE digestion analysis. Clones that displayed 
similar RE digest banding patterns were grouped together and considered duplicates of the 
same cDNA. A single representative clone was selected from each group and co-transformed 
into competent cdc25h yeast cells with pSOS:Tbx-Nrep, to confirm galactose-dependent 
growth at 37° C. Clones that continued to demonstrate galactose-dependent growth were 
considered positive interactions. Plasmid DNA from positive clones was sequenced and 
analyzed by BLAST analysis (Altschul et al., 1990) for gene identification. 
For the deletion studies, yeast competent cells were co-transformed with pSOS:Tbx2-
Nrep and either Uspl or Caper-a deletion constructs fused to the myristylation signal coding 
sequence (described above). Colonies were assayed for galactose-dependent growth at 37° C. 
Three separate transformations were carried out for each putative positive clone and three to 
five colonies were selected from each transformation and evaluated for their ability to grow 
at the selective temperature. 
Co-immunoprecipitations and western blot analysis 
Cos7 cells were grown on 10-cm plates to 90-95% confluency and co-transfected 
with 2 p,g of pcDNA3:Tbx2 and 2 |xg of either pHA:Uspl, pHA:Caper-a or pCMV:HA 
vector, with Lipofectamine2000 transaction reagent (Invitrogen) according to the 
manufacturer's protocol. After transaction, cells were incubated at 37° C in an atmosphere 
of 5% CO2 for 48 hours. Subsequently, cells were collected in 1 ml of cell lysis buffer (50 
mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.25% Sodium deoxycholic acid, 1 mM 
NasV04, 1 mM NaF, 1 mM PMSF, and 1 gg/ml each Aprotinin, Pepstatin, and Leupeptin). 
Protein concentrations were determined with DC Lowry Assay according to the 
manufacturer's protocol (Bio-Rad Laboratories). Extracts were diluted with phosphate 
buffered saline (PBS) to equal protein concentrations and incubated at 4° C overnight with 10 
(il/ml of either Tbx2 anti-sera (Upstate USA) or 10 jxl/ml polyclonal anti-HA antibody (Santa 
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Cruz Biotechnology). Samples were then incubated with 15 (J.1 Pansorbin® cells 
(Calbiochem) for 2 hours at 4° C and collected by centrifugation at 10,000 g for 15 seconds. 
Immuno-precipitates were washed three times with ice-cold PBS followed by brief 
centrifugation at 14,000 rpm to collect the Pansorbin® cells. The pellet was resuspended in 
50 p.1 of 2x Laemlli's buffer (125 mM Tris-HCl pH 6.8, 10% sodium do-decyl sulfate (SDS), 
10% glycerol, 130 mM dithiothreitol, bromophenol blue) per milliliter of the original cell 
lysate. After boiling for 5 minutes, proteins were size separated by SDS-polyacrylamide gel 
electrophoresis and transferred to PVDF membrane. Membranes were probed with Tbx2 
anti-sera (Upstate USA) followed by horse-radish peroxidase-conjugated secondary 
antibody, or secondary antibody alone. Expression of Tbx2 protein was visualized with the 
enhanced chemiluminescent plus detection system (Amersham Biosciences) as described by 
the manufacturer. 
Transient transfection assays 
Cos? or CH3 10T1/2 cells were plated in 6-well plates at 8,000 cells/cm2. The 
following day, cells were co-transfected with 250 ng G3PDH-5Gal-Luc, and 25-125 ng of 
either effector plasmid or empty vector to compensate. A |3-galactosidase expression vector 
(25 ng) was co-transfected into each treatment to analyze for transfection efficiency. All 
transactions were repeated a minimum of three times, with three replicates per treatment. 
Small inhibitory RNA (siRNA) transfection assays 
Caper-a siRNA constructs were tested to determine the extent to which they could 
abrogate Caper-a function. C3H/10T1/2 murine fibroblast cells were co-transfected with 
G3PDH-5Gal-Luc reporter (250 ng) in combination with 100 ng of empty pBind vector or 
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pB:Caper-a expression vector and 800 ng of siRNA expression vector. The siRNA 
treatments included 1) GFP siRNA as control, 2) Caper-1 siRNA, 3) Caper-2 siRNA or 4) 
Caper-1 siRNA (400 ng) in combination with Caper-2 siRNA (400 ng). To analyze the 
ability of Caper-2 siRNA to abrogate repression induced by the n-terminal repression domain 
of Tbx2, the G3PDH-5Gal-Luc reporter (250 ng) was co-transfected into C3H/10T1/2 
murine fibroblast cells with 100 ng of pB:Tbx2-Nrep expression vector and 800 ng of either 
GFP siRNA control (or Caper-2 siRNA. After transfection, cells were grown at 37° C in an 
atmosphere of 5% CO2 for 48 hours in either Eagle's minimal essential growth media for 
C3H/10T1/2 cells (Atlanta Biologicals) or in Dulbecco's modified Eagle's medium for Cos? 
cells (Atlanta Biologicals), supplemented with 2 mM L-glutamine and 10% Fetal Bovine 
Serum. Cells were harvested in lx Reporter Lysis Buffer (Promega), centrifuged at 14,000 
rpm for 1 minute, and luciferase activity was quantified with a TD-20/20 luminometer 
(Turner Design). To assay for beta-galactosidase activity, 5-10 pi of cell extract was mixed 
with 100 (il of Z-buffer (60 mM Dibasic Na^FlPC^, 40 mM Monobasic NaaHPC^, 10 mM 
KC1, 1 mM MgSC>4, 39 mM (3-mercaptoethanol). Twenty microliters of 4 mg/ml Ortho-
Nitrophenol-Beta-Galactoside (ONPG) in Z-buffer was added to each sample and samples 
were incubated at 37° C until a yellow color was observed. Beta-galactosidase activity was 
measured with a PowerWaveHT microplate spectrophotometer (Bio-Tek). Protein 
concentration was quantified with Bradford Reagent (Bio-Rad Laboratories) as described by 
the manufacturer. Luciferase activity was standardized to beta-galactosidase activity and 
protein concentration. 
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In situ probes and whole mount in situ hybridization 
Digoxigenin (DIG)-labelled RNA probes were generated with the maxiscript 
transcription kit (Ambion). Each transcription reaction contained 1 (o.g of linearized plasmid, 
lx transcription buffer, 40 units of RNA Polymerase, and 10 (iM rNTPs that included 4 pM 
DIG-UTP (Roche) in a final volume of 20 jj.1. Transcription reactions were incubated at 37° 
C for 2 hours after which 1 jal of DNase I was added and incubated for 15 minutes. Free 
nucleotides were removed either by ethanol precipitation of the riboprobe, or by NucAway 
column purification (Ambion) as described by the manufacturer. 
Murine embryos were collected at e9.5 or el0.5. Embryos were fixed for 4 hours to 
overnight in MEMPFA [0.1 M 3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.4, 2 
mM EGTA, 1 mM MgSCU, 3.7% paraformaldehyde] at 4° C, washed for five minutes with 5 
M NaCl and stored in 90% Methanol at -20° C. Embryos were re-hydrated in a series of 
washes that contained progressively lower level of methanol (75%, 50%, 25%), followed by 
phosphate buffered saline that contained 0.1% Tween-20 (PBT). 
Embryos were pre-treated with 6% H2O2 for 7 minutes at room temperature (R/T) and 
washed three times with PBT for five minutes at R/T. The embryos were then treated with 
10 |ig/ml proteinase K for 10 minutes at R/T, washed with freshly prepared glycine (2 
mg/ml) in PBT to terminate proteinase K digestion and washed twice with PBT. Post-
fixation of the embryos was performed with 0.2% glutaraldehyde/0.4% paraformaldehyde in 
PBT for 20 min at R/T, followed by 3 washes in PBT at R/T for 5 minutes. 
Embryos were pre-hybridized in hybridization solution {50% deionized formamide, 
5x SSC (0.75 M sodium chloride, 75 mM sodium citrate), 2% blocking reagent (Roche), 
0.1% Tween 20, 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate 
(CHAPS), 50 ng/ml yeast RNA, 5 mM EDTA, 50 pg/ml heparin} for 3 hours at 65° C, and 
hybridized overnight in 1 ml hybridization solution that contained 300 ng/ml of DIG-labelled 
Caper-a, Uspl or Tbx2 anti-sense riboprobe. Four hundred microliters of 2x SSC (pH 4.5) 
was added to the hybridization solution and incubated at 65° C for five minutes. The SSC 
addition and incubation was repeated two additional times. The mixture was removed and 
the embryos were washed twice in 0.1% CHAPS/2x SSC at 65° C for 30 minutes. Embryos 
were treated with 20 gg/ml RNase A in 0.1% CHAPS/2x SSC for 1 hour at 37° C followed 
by two 10 minute washes in maleic acid buffer (MAB: 100 mM maleic acid & 150 mM NaCl 
pH 7.5) at R/T, two 30 minute washes in MAB at 70° C, two 10 minute washes in PBS at 
R/T and one 5 minute wash in PBT at R/T. The embryos were blocked with blocking 
solution (10% heat inactivated sheep serum, 1% bovine serum albumin, 0.1% Tween 20 in 
PBS) for 3-4 hours. 
Embryos were incubated with pre-adsorbed alkaline phosphatase-conjugated Fab 
fragments of anti-DIG antibodies (Haramis, 2000) overnight at 4° C with gentle agitation. 
The Fab fragment solution was removed and embryos were washed for 45 minutes five times 
in PBT that contained 0.1% bovine serum albumin at R/T. Embryos were subsequently 
washed for 30 minutes two times in PBT, followed by three 10 minute washes in fresh 
NTMT buffer pH 9.5 (100 mM NaCl, 100 mM Tris-Cl, pH 9.5, 50 mM MgC12, and 0.1% 
Tween 20), at R/T. Expression patterns were visualized via color precipitate reaction using 
lx NBT/BCIP substrate solution (Roche) in NTMT buffer. 
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RT-PCR 
Individual tissues were collected from C57BL/6J adult female mice and treated with 
Trizol reagent (Invitrogen) as described by the manufacturer for total RNA isolation. First-
strand cDNA was synthesized from 5 pg total RNA with Superscript II Reverse 
Transcriptase (Invitrogen) according to the manufacturer's protocol. Uspl cDNA was PCR 
amplified with the primers N104Sacl (5'-GAA TTC CAT GAG CTT TCC AAG GTC GAG 
GAG A-3') and N104Sac2 (5'-CTC GAG TCA ACC ACA AAA TTC CCC TCA TCG-3') 
(Integrated DNA Technologies). As control, rat Gapdh sense primer (5'-TGA TGA CAT 
CCA GAA GGT GGT GAA A-3') and anti-sense primer (5'-TCC TTG GAG GCC ATG 
TAG GCC AT-3') were used to detect the ubiquitously expressed Gapdh message. 
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Figure 1 -Protein-protein interactions from Cos? cell lysates demonstrated by co-
immunoprecipitation. Cos? cells were were co-transfected with 2 jig each of 
pcDNA3:Tbx2 (lanes 1-4) or pcDNA3 (lane 5) and either pHA:Caper-a (lanes 1-2), 
pHA:Uspl (lanes 4-5) or pCMV:HA (lane 3). Immunoprecipitations were performed with 
Tbx2 anti-sera (lanes 2 & 5) to serve as Tbx2 controls, or HA antibody (lanes 1, 3 & 4). The 
membrane was probed with Tbx2 anti-sera to visualize Tbx2 protein that was pulled down by 
Tbx2 anti-sera, as control (lane 2), or that had co-immunoprecipitated with either HA:Caper-
ex (lane 1) or HA:Uspl (lane 4). In contrast, Tbx2 was not observed in cell lysates that had 
been transfected with empty pcDNA3 vector (lane 5) or that expressed the HA tag alone 
(lane 3). 
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A 
NH3 
Wild-type Usp1 _____ 
a Usp1:345-784* 
b Usp1:345-414 
c Usp1:345-470 
d Usp1:384-449 
e Usp1:463-615 
f Usp1:345-764 
Figure 2 -Interaction of Tbx2 with the deubiquitinase Usp1. A) Schematic of Uspl 
deletion constructs and the delineation of the region within Uspl that interacted with Tbx2. 
* Corresponds to the protein fragment encoded by the cDNA originally identified in the yeast 
2-hybrid screen. Column on the right titled "Growth" identifies the Uspl deletion constructs 
that interacted with SOS:Tbx2-Nrep, indicated by growth on selective galactose media at the 
restrictive temperature of 37° C. B) Culture plates depicting selective growth indicative of 
bait-target interactions. Alphabetical labels correspond with the respective constructs 
schematically represented in A. UCH=ubiquitin carboxy-terminal hydrolase domain, 
Glu-Glucose media, Gal=Galactose selection media, 25==Permissive temperature of 25° C 
and 37=Restrictive temperature of 37° C. 
COOH 
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COOH 
Growth 
Tbx2-82/285 ##mimm=========a + 
Tbx2-515/574 Pit 
Figures -Schematic of bait constructs for yeast 2-hybrid screen. The bait constructs 
are diagrammed along with the full-length Tbx2 protein. The Tbx2-Nrep construct encodes 
Tbx2 residues 1-87 with a deletion of residues 54-77. The @9 represents the SOS portion of 
the fusion protein. and Hi represent the two repression domains identified within Tbx2 
and D represents the DNA binding domain of Tbx2. The "Growth" column on the right 
identifies the bait constructs tested for their ability to interact with Uspl. nt=not tested. 
Wild-type Tbx2 
Tbx2-Nrep 
(Tbx2-1/53,78/87) 
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Wild-type Caper-a "• 
a Cpr 318-530* 
b Cpr 318-392 
c Cpr 318-376 
d Cpr 318-356 
e Cpr 318-415 
f Cpr 392-517 
g Cpr 392-483 
h Cpr 392-450 
i Cpr 392-417 
Figure 4 -Interaction of Tbx2 with Caper-a. A) Schematic of Caper-a deletion constructs 
and delineation of the region within the Caper-a protein that interacted with Tbx2. 
* Corresponds to the protein fragment encoded by the cDNA originally identified in the yeast 
2-hybrid screen. Column on the right titled "Growth" identifies the Caper-a deletion 
constructs that interacted with SOS:Tbx2-Nrep, indicated by growth on selective galactose 
media at the restrictive temperature of 37° C. B) Culture plates depicting selective growth 
indicative of bait-target interactions. Alphabetical labels correspond with the respective 
constructs schematically represented in A. Glu=Glucose media, Gal=Galactose selection 
media, 25=Permissive temperature of 25° C and 37=Restrictive temperature of 37° C. 
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Figure 5 -Investigation into potential gene regulation via Uspl and Tbx2 interaction. 
Cos? cells were transfected with 250 ng of reporter gene and indicated amounts of effector 
vectors plus empty vector to compensate. Cell extracts were prepared after 48 hours and 
analyzed for luciferase activity. Bar diagrams show least square means ± standard errors of 
three independent experiments tested in triplicate. A) Cos? cells were transfected with 
increased amounts of pB:Uspl. B) Cos? cells were transfected with pB:Uspl (25 ng) and 
indicated amounts of pcDNA3:Tbx2. Different superscripts denote different levels of 
significance (pO.Ol). C) Cos? cells were co-transfected with either control vector or 
pB:Tbx2 (25ng), and increased amounts of pcDNA3:Uspl. Different superscripts indicate a 
significant difference (p<0.01). 
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Figure 6 -Investigation into potential gene regulation via Caper-a and Tbx2 
interaction. C3H/10T1/2 cells were co-transfected with 250 ng of reporter gene and 
indicated amounts of effector vectors. Cell extracts were prepared after 48 hours and 
analyzed for luciferase activity. Bar diagrams show least square means ± standard errors of 
three independent experiments tested in triplicate. A) C3H/10T1/2 cells were transfected 
with 100 ng of either pB:Caper-a or pBind. B) C3H/10T1/2 cells were transfected with 
pB:Caper-a (100 ng) and 800 ng of siRNA expression vector. C) Caper-2 siRNA did not 
abrogate repression by Gal4:Tbx2-Nrep. CH3 10T1/2 cells were co-transfected with reporter, 
100 ng of either pBind or pB:Tbx2-Nrep and 800 ng of either GFP-siRNA, or Caper-2 
siRNA. Different superscripts indicate different levels of significance (p<0.01) for each 
panel. 
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Figure 8 -Expression of Uspl in adult mouse tissues. Expression of Uspl message in 
adult mouse tissues was detected by RT-PCR. A. Amplification of Uspl from cDNA 
samples. B. Amplification of ubiquitous Gapdh, as control, (st) stomach; (sp) spleen; (si) 
small intestine; (ht) heart; (lv) liver; (lg) lung; (sm) skeletal muscle; (kd) kidney; (sk) skin; 
(ad) adipose; and (br) brain. 
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Table 1a 
Protein Full name GI Accession # Proposed function 
Uspl 
(2) 
Ubiquitin specific 
processing protease 1 
17390389 Deubiquitination of FANCD-2 
[Nijman et al., 2005] 
Caper-a 
(4) 
Coactivator of activating 
protein-1 and estrogen 
receptors 
17063212 Transcriptional cofactor and 
alternative splicing factor [Dowhan 
et al., 2005] 
Rpl5 
(4) 
Ribosomal protein 15 53734118 Nucleocytoplasmic trafficking 
[Rosorius et al., 2000] 
Hnmphl 
(1) 
Hetergeneous nuclear 
ribonucleoprotein HI 
27769211 Suppression of smooth muscle 
myogenesis [Liu et al., 2001] 
Psmc3 
(1) 
Proteosomal Subunit 
(macropain) ATPaseS 
13543236 Blastocyst development [Sakao et 
al., 2000] i 
s 
Nascent polypep tide-
associated complex alpha 
54035589 NAC complex formation with the 
ribosome [Beatrix et al., 2000] 
Table 1b 
Protein Full name GI Accession # Proposed function 
Uspl 
(2) 
Ubiquitin specific 
processing protease 1 
17390389 Deubiquitination of FANCD-2 
[Nijman et al., 2005] 
Eddl 
(4) 
E3 ubiquitin protein ligase, 
HECT domain containing, 1 
37046903 Ubiquitination, based on the 
presence of the HECT domain 
[Huibregtse et al., 1995] 
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CHAPTER 4: General Conclusions 
T-box proteins are expressed dynamically throughout embryogenesis and 
misregulation of several of these proteins has had severe development consequences. 
However, there is still much that is unknown about T-box proteins and their individual 
functions. To better understand the developmental significance of T-box proteins, their 
regulation and functional roles need to be clarified. This research has focused on one of 
these proteins: Tbx2. Tbx2 appears to play significant roles in delineation of heart chambers 
and development of the heart valves. Though developmental problems in humans have not 
yet been associated with Tbx2, its roles in cardiogenesis make it a potential candidate for 
CHD. The overall objective of this research was to better understand the functional roles of 
Tbx2 through characterization of the Tbx2 protein and identification of interactive protein 
partners. 
Characterization of the Tbx2 protein confirmed the repressive properties of a putative 
carboxy-terminal repression domain. A second repression domain was also identified at the 
amino-terminus (Paxton et al., 2002). A mechanism of repression for the C-terminal domain 
has since been proposed (Vance et al., 2005), but how the N-terminal domain induces 
repression is still unclear. Furthermore, in addition to the two repression domains, a small 
activation domain was identified at the amino-terminus of the T-box. Activation by this 
domain appeared to depend on promoter context (Paxton et al., 2002). Recent work by 
Barron and colleagues (2004) demonstrated that Tbx2 could activate the SRF promoter. A 
mechanism for how Tbx2 transactivated this promoter is currently unknown, but it was 
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suggested that multiple T/2-sites arranged in tandem in the SRF promoter may have provided 
an appropriate context for activation, rather than repression, by Tbx2 (Barron et al., 2004). 
It has been suggested that functional specificity of T-box proteins may be determined 
by their interactions with other proteins (review by Tada and Smith, 2001). To identify 
proteins that interact with Tbx2, a yeast 2-hybrid system was used to screen an e9.5 whole 
mouse library. Six proteins that potentially interacted with Tbx2 were identified, of which 
Uspl and Caper-a were selected for further characterization. Interactions of Tbx2 with 
either Uspl or Caper-a were further demonstrated with full-length proteins by co-
immunoprecipitation analysis. 
Although Tbx2 was shown to interact with Caper-a and with Uspl, both in yeast and 
mammalian systems, all attempts to identify a role for these interactions in the regulation of 
gene transcription were unsuccessful. The work performed to investigate potential roles for 
the interaction between Tbx2 and Caper-a or Uspl in gene regulation is described in 
Appendices A and B of this dissertation, respectively. Regulation of transcription was 
observed in a few isolated cases. For example, Tbx2 and Gal4:Uspl significantly activated 
promoter activity, while Gal4:Uspl demonstrated a very mild activation that only bordered 
on significance. Also, Gal4:Caper-a could repress promoter activity in CH3 10T1/2 cells, 
but was transcriptionally inert in a Cos? cell line. Taken together however, the 
comprehensive results indicate that neither the Tbx2 and Caper-a, nor the Tbx2 and Uspl 
interactions appeared to regulate gene transcription. 
Some correlative data was obtained to support the argument that these proteins may 
interact in some cellular processes. Expression patterns of both Caper-a and Uspl mRNA 
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were visualized by in situ hybridization. In addition, Uspl expression was detected by RT-
PCR analysis from adult murine tissues. With utilization of these techniques, both Caper-a 
and Uspl mRNAs were found in multiple tissues where Tbx2 expression has also been 
reported. Therefore, areas of co-expression have been identified where these Tbx2-protein 
interactions could occur in vivo, including the optic vesicle, otic vesicle and branchial arches. 
Although capabilities for gene regulation were not observed for the interactions 
between Tbx2 and Caper-a or Uspl, functional roles in other cellular processes cannot be 
ruled out. In the case of Uspl, some preliminary work was performed to create groundwork 
for future investigation of potential roles in cellular proliferation or subcellular localization. 
These studies are outlined in Appendix C of this dissertation. The initial results may indicate 
a potential role for Uspl in the cellular localization of Tbx2. A shift towards robust nuclear 
localization of Tbx2 was observed in cells that also expressed a GFP:Uspl fusion protein. 
Future work with Uspl should include further characterization of this potential role in 
nuclear localization of Tbx2. In particular, a defined system in which Tbx2, Uspl or both 
proteins are endogenously expressed should be established. This will help to determine if 
Uspl truly shifts Tbx2 localization, or if the results obtained in the preliminary study 
reported may be a result of nuclear retention of Tbx2 simply due to the overexpression of 
Uspl, a nuclearly localized protein. Furthermore, the demonstration of an ubiquitin-Tbx2 
conjugate would further substantiate the argument for an interaction between Tbx2 and Uspl 
in this or some alternative function. 
An alternative role for the interaction between Tbx2 and Caper-a may involve the 
splicing capabilities of Caper-a. It is possible that Caper-a interacts with Tbx2 to induce 
splice variants of Tbx2 targets. This hypothesis is further substantiated by the fact that three 
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of the six proteins herein identified to interact with Tbx2 were also present in a splicesome 
complex. In addition, known Tbx2 targets, including Nkx2.5, which was shown to be 
regulated by Tbx2 in this work, have alternative splice variants. There is an opportunity, 
therefore, to explore a potential role for Caper-a in the splicing of Tbx2 downstream targets. 
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APPENDIX A. Caper-a was Not Required for the Ability of 
Tbx2 to Repress a Minimal Nkx2.5 Promoter 
Explanatory Note 
Tbx2 repressed several Nkx2.5 promoter constructs. A minimal promoter that lacked 
known T-box binding elements (TBEs) was constructed. Interestingly, Tbx2 also repressed 
the minimal promoter. Further analysis of the minimal promoter identified three AP-1 sites. 
Caper-a has been shown to interact with AP-1 (Jung et al., 2002). In Chapter 3 Caper-a was 
identified as an interactive partner of Tbx2. It was thought that Caper-a may have recruited 
Tbx2 to the minimal Nkx2.5 promoter through interactions with both Tbx2 and either AP-1 
or another protein. Localization of Tbx2 to the promoter in this manner could have enabled 
Tbx2 to repress the minimal promoter, even in the absence of a T-box binding site. RNA 
interference analysis was used to test the hypothesis that Caper-a recruited Tbx2 to the 
minimal Nkx2.5 promoter. Knock-down of Caper-a by siRNA demonstrated that Caper-a 
was not required for the ability of Tbx2 to repress a promoter that lacked known T-box ex­
acting elements. Therefore, Caper-a did not appear to recruit Tbx2 to the promoter. 
Experimental Procedures 
Plasmids and constructs 
Wild-type Tbx2 expression vector was provided by Dr. Roni Bollag (Chen et al., 
2001). Wild-type Caper-a expression vector was provided by Dr. Jae Woon Lee (Jung et al., 
2002). To generate the pcDNA3:Caper-a anti-sense construct, Caper-a cDNA was isolated 
by BamHI-Acc65I restriction endonuclease (RE) digestion from pB:Caper-a (Chapter 3) and 
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cloned into the BamHI-Acc65I sites of pcDNA3 (Invitrogen). The Caper-2 and GFP siRNA 
expression constructs were kindly provided by Dr. Dennis Dowhan. 
The following Nkx2.5 promoter deletion constructs were generated by RE digestion: 
-3512D (Xbal), -3220 (NotI), -2061 (Nrul) and -864 (Avril; Reecy, unpublished data). To 
generate the Nkx2.5 minimal promoter (-467/-171), a minimal promoter fragment was PCR 
amplified with the primers (5'-CGA GGA TCC CTG AAA ATA ACC CC-3') and (5'-GAC 
AAG CTT CAC CTA ATA TAG AC-3') from the -3512D Nkx2.5 promoter construct 
(Reecy et al., 1999). The amplified PCR product was ligated into the pGEM-T Easy vector 
(Promega) and subsequently cloned into Bglll-Hindlll sites pGL3-Basic (Promega) as a 
BamHI-Hindlll fragment to drive luciferase activity. 
Transfection assays 
Cos7 cells were plated at 8,000 cells/cm2. The following day, cells were co-
transfected with 400 ng reporter, and 100 ng of either Tbx2 or empty vector as control. A P-
galactosidase expression vector (25 ng) was co-transfected into each treatment to analyze for 
transfection efficiency. All transactions were repeated a minimum of three times, with three 
replicates per treatment. 
Small inhibitory RNA (siRNA) transfection assays 
CH3 10T1/2 murine fibroblast cells were co-transfected with a minimal Nkx2.5 
(-467/-171) promoter driven luciferase reporter (400 ng) in combination with 100 ng of Tbx2 
expression vector and 800 ng of either GFP siRNA expression vector as control, or Caper-2 
siRNA. 
After transfection, cells were grown at 37° C in an atmosphere of 5% CO% for 48 
hours in either Eagle's minimal essential growth media for 10T1/2 cells (Atlanta Biologicals) 
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or in Dulbecco's modified Eagle's medium for Cos7 cells (Atlanta Biologicals), 
supplemented with 2 mM L-glutamine and 10% Fetal Bovine Serum. Cells were harvested 
in lx Reporter Lysis Buffer (Promega), centrifuged at 14,000 rpm for 1 minute, and 
luciferase activity was quantified with a TD-20/20 luminometer (Turner Design). To assay 
for beta-galactosidase activity, 5-10 pi of cell extract was mixed with 100 (J.1 of Z-buffer (60 
mM Dibasic NazHPC^, 40 mM Monobasic NaaHPO,*, 10 mM KC1,1 mM MgSC>4, 39 mM |3-
mercaptoethanol). Twenty microliters of 4 mg/ml Ortho-Nitrophenol-Beta-Galactoside 
(ONPG) in Z-buffer was added to each sample and samples were incubated at 37° C until a 
yellow color was observed. Beta-galactosidase activity was measured with a PowerWaveHT 
microplate spectrophotometer (Bio-Tek). Protein concentration was quantified with 
Bradford Reagent (BioRad) as described by the manufacturer. Luciferase activity was 
standardized to beta-galactosidase activity and protein concentration. 
Results & Discussion 
Tbx2 repressed a minimal 
Nkx2.5 promoter 
Tbx2 repressed the 
Nkx2.5 downstream promoter 
(-3512D) in cell culture (Fig. 1). 
Several promoter constructs with 
sequential deletions from the 5' 
end of -3 512D were also 
repressed by Tbx2. Sequence 
Dcccms 
$ Q6 
K Q0 
-3512D -3220 -2061 -864 -467/-171 
Figure 1. Repression of several Nkx2.5 promoter constructs by 
Tbx2. Cos? cells were co-transfected with 400ng of the 
indicated reporter and 100 ng of either pcDNA3 or 
pcDNA3:Tbx2. Cells were harveseted after 48 hours and 
analyzed for luciferase activity. The bar diagram shows the 
mean normalized luciferase activity ± standard error. Each 
treatment was tested in triplicate in three independent 
experiments. * Reflects statistical differences between 
treatments of each promoter p<0.02. 
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analysis of the -3512D promoter identified several potential T-box binding elements (TBEs). 
A minimal Nkx2.5 promoter construct was produced to further analyze the ability of Tbx2 to 
repress the Nkx2.5 promoter. This minimal promoter contained 296 bp upstream of the start 
codon of exon 1, and was free of known TBEs. Interestingly, Tbx2 still repressed the 
minimal Nkx2.5 promoter (-467/-171) (Fig. 1). 
Caper-a knock down did not abrogate Tbx2 repression ofNkx2.5 minimal promoter 
Upon closer examination of the minimal Nkx2.5 promoter, three AP-1 cz's-acting 
elements were identified. Since Caper-a has been shown to interact with AP-1, it was 
hypothesized that Caper-a could recruit Tbx2 to the minimal Nkx2.5 promoter to elicit 
promoter repression. In some initial studies, expression of Caper-a antisense RNA abrogated 
the repression of the Nkx2.5 minimal promoter by Tbx2. Repression of the promoter by 
Tbx2 was completely abrogated when cells were transfected with 800 ng of plasmid DNA 
that expressed Caper-a antisense RNA (Data not shown). However, knock-down of 
Gal4:Caper-a function by Caper-a antisense RNA could not be confirmed, so the 
experiments were repeated with the Caper-2 siRNA construct. Fibroblast cells were 
transiently co-transfected with Nkx2.5-min-luc, along with either pcDNA3:Tbx2 or empty 
vector in combination with either the pCaper-2 siRNA construct or pGFP-siRNA control. In 
the presence of GFP-siRNA control, Tbx2 repressed the minimal Nkx2.5 promoter activity 
approximately 60%, as compared to the control treatment, which contained empty pcDNA3 
expression vector. Tbx2 repressed the minimal Nkx2.5 promoter activity to the same degree 
in the presence of Caper-2 siRNA as compared to the empty vector control (Fig. 2). These 
results indicate that Caper-a was not required for Tbx2 repression of the minimal Nkx2.5 
promoter activity. It is possible that an uncharacterized TBE may be present in the minimal 
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GFP siRNA Caper-2 siRNA 
promoter, or that Tbx2 interacts 
with some other endogenous DNA-
binding protein. However, because 
Caper-a was not required for Tbx2 
repression of the Nkx2.5 promoter, 
it was concluded that Caper-a did 
not recruit Tbx2 to the promoter. 
Conclusions 
The purpose of this 
research was to investigate the 
potential role of Tbx2 and Caper-a 
interaction in the regulation of 
gene transcription. Tbx2 was 
shown to repress an Nkx2.5 
minimal promoter which lacked any known TBEs. The hypothesis that Caper-a could recruit 
Tbx2 to the Nkx2.5 minimal promoter was tested by RNA interference analysis. However, 
knock-down of Caper-a by siRNA did not affect repression the Nkx2.5 minimal promoter by 
Tbx2. These results indicated that Caper-a was not required for Tbx2 repression of this 
promoter. Therefore, Caper-a did not appear to recruit Tbx2 to the minimal Nkx2.5 
promoter. 
Figure 2. Caper-2 siRNA did not abrogate Tbx2 repression 
of Nkx2.5-min-luc. CH3 10T1/2 cells were co-transfected 
with 400 ng of Nkx2.5-min-luc and 100 ng of either pcDNA3 
or pcDNA3:Tbx2. Cells were harveseted after 48 hours and 
analyzed for luciferase activity. The bar diagram shows the 
mean normalized luciferase activity ± standard error. Each 
treatment was tested in triplicate in three independent 
experiments. Differing superscripts reflect statistical 
differences between treatments pO.Ol. 
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APPENDIX B: Further Investigation into the interaction 
between Tbx2 and Usp1 
Explanatory Note 
The focus of this project was to identify proteins that interact with Tbx2 to provide a 
mechanism for Tbx2 induced repression. The work detailed in Chapter 3 focused on the 
identification and characterization of an interaction between Tbx2 and Uspl. Potential sites 
of interaction were identified in vivo, based on patterns of co-expression and potential role 
for that interaction in the regulation of gene transcription was investigated. However, 
because the Tbx2/Uspl interaction did not appear to regulate transcription some additional 
work was performed to investigate potential roles for the interaction between Tbx2 and Uspl 
in other cellular processes. Specifically, some preliminary experiments were performed to 
investigate potential roles for this interaction in cellular proliferation and protein localization. 
The data reported in this appendix is preliminary and was performed to lay the groundwork 
for future investigations into potential roles for an interaction between Tbx2 and Uspl 
outside of gene regulation. 
Experimental Procedures 
Plasmids and Constructs 
Wild-type Tbx2 expression vector (pcDNA3:Tbx2) was kindly provided by Dr. Roni 
Bollag (Chen et al., 2001). Generation of pcDNA3:Uspl was previously described in 
Chapter 3. The pcDNA3:Uspl-C90S mutant was constructed with the QuikChange® II site 
directed mutagenesis kit (Stratagene), as described by the manufacturer. The primers used to 
generate Uspl:C90S were Usp-C90S-l (5'-TGA ATA ACC TTG GCA ACA CTA GTT 
ATC TGA-3') and Usp-C90S-2 (5'-CCT GAA GAA TAC TAT TCA GAT AAC TAG TOT­
S'), which introduced a point mutation in the coding sequence that resulted in a cysteine to 
serine amino acid substitution at amino acid 90 of the Uspl protein. The Uspl siRNA vector 
Uspl-c, and the green fluorescent protein (GFP):Uspl fusion expression vector (pGFP:Uspl) 
were kindly provided by Drs. Alan D'Andrea and Rene Bernards (Nijman et al., 2005). 
Cell culture 
Cos7 cells were cultured in Dulbecco's modified Eagle's medium (Atlanta 
Biologicals) supplemented with 2 mM L-glutamine and 10% fetal bovine serum (culture 
media). Cells were grown in a humidified chamber at 37° C in an atmosphere of 5% CO2. 
Construction of stable cell populations 
To generate stable cell populations, Cos? cells were plated on eight 10-cm plates and 
grown to approximately 90% confluency. Plates were transfected with 1 jig total plasmid 
DNA that had been linearized by Bglll RE digestion. Each plate was transfected with one of 
the following plasmids: pcDNA3, pcDNA3:Tbx2, pcDNA3:Uspl or pcDNA3:Uspl-C90S. 
Additional plates were co-transfected with pcDNA3:Tbx2 in combination with either 
pcDNA3:Usp 1, pcDNA3:Usp 1-C90S or Uspl-c. A final plate was co-transfected with Usp 1 -
c in combination with pcDNA3. The pcDNA3 backbone contained a neomycin expression 
cassette which confers resistance to neomycin under selective growth conditions. DNA was 
transfected into cells with Lipofectamine2000 (Invitrogen) as described by the manufacturer. 
Plates that were transfected with two plasmids were co-transfected with 500 ng of each 
plasmid, for a total of 1 |ig DNA. After transaction, cells were grown for 24 hours, treated 
with 0.25% trypsin for two minutes to remove them from the 10-cm plate, and equally 
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distributed onto three 60-mm plates. Cells were grown in selective culture media that 
contained 500 |ig/ml Geneticin (Gibco) for 14 days to select for cells that demonstrated 
resistance to neomycin, indicative of transfection with pcDNA3 vector backbone. Selective 
media was replaced every 2-3 days. 
Proliferation Assays 
Stable cell populations were plated at 25,000 cells per well on 6-well plates. Cells 
were grown for 24 hours and then treated with 5 -Bromo-2 ' -deoxy-Uridine (BrdU) at a final 
concentration of 1 p.g/ja.1 for 4 hours. Cells were rinsed twice with phosphate buffered saline 
(PBS) and fixed for 30 minutes with PBS that contained 1% Paraformaldehyde and 0.5% 
Sucrose. Cells were treated for 15 minutes with 4 M HC1, rinsed twice with PBS and 
incubated at room temperature (R/T) for 4 minutes in PBS that contained 1% IGEPAL 
(SigmaAldrich). Cells were rinsed twice with PBS that contained 1% Tween-20 (PBS-T). 
Cells were incubated in PBS-T that contained 1% bovine serum albumin (BSA) and a 1:100 
dilution of BrdU primary antibody (Developmental Studies Hybridoma Bank, Iowa City, IA) 
at 4° C overnight. Primary antibody was removed and cells were washed three times with 
PBS-T for 5, 10 and 15 minutes respectively. Cells were then incubated with a 1:500 
dilution of FITC secondary antibody (SigmaAldrich) in PBS-T that contained 1% BSA for 1 
hour at R/T. Cells were washed three times with PBS-T for 5, 10, and 15 minutes 
respectively. Cells were treated with PBS-T that contained 10 (xg/ml Hoescht's nuclear dye 
(H033258; SigmaAldrich) for 10 minutes. The H033258 stain and FITC fluorescence were 
observed with a Nikon fluorescent microscope. A single experiment was performed with 
three replicates per experimental treatment. Ten fields per experimental unit were scored for 
the number of FITC positive cells and total cell number. 
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Cellular localization of Tbx2 
Sterile glass coverslips were placed in a 12-well plate (Fischer Scientific Inc.) and 
treated with PBS that contained 10 ng/ml fibronectin (SigmaAldrich) for 30 minutes. 
Coverslips were then rinsed with culture media. Cos? cells were plated at a density of 
40,000 cells per well and grown overnight. 
Cells were co-transfected with 200 ng each of pcDNA3:Tbx2 and either pEGFP-Cl 
(ClonTech), or pGFP:Uspl. Transactions were performed with Lipofectamine2000 
(Invitrogen) as described by the manufacturer, and cells were grown for 48 hours. Cells were 
rinsed twice with PBS and fixed for 15 minutes with ice cold 50:50 Acetone:Methanol. Cells 
were rinsed twice with PBS, treated for five minutes with PBS that contained 1% IGEPAL 
(SigmaAldrich), then blocked with PBS that contained 5% goat serum, 0.4% BSA and 0.2% 
Triton X-100 for 20 minutes at R/T. 
Coverslips were incubated in PBS that contained a 1:1000 dilution of Tbx2 primary 
antibody (Jacobs et al., 2000) at 4° C overnight. Coverslips were rinsed twice in PBS and 
then incubated in PBS that contained a 1:1000 dilution of Alexa594-conjugated secondary 
antibody (Molecular Probes), and 10 ng/ml H033258 for 90 minutes at R/T. Coverslips 
were rinsed twice in PBS, rinsed twice with distilled water, allowed to dry for approximately 
2 minutes then placed face down on a microscope slide that contained ~4 p.1 of VectaShield 
(Vector Laboratories). The edge of the coverslip was sealed with nail polish and the cells 
were analyzed for GFP, Alexa594 and H033258 nuclear staining by immunofluorescent (IF) 
microscopy. A single experiment was performed that included 2 replicate coverslips per 
treatment. Analysis was performed on a Zeiss photomicroscope III with a 40x phase 
objective. Images were obtained with a Spot RT digital camera. 
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Results and Discussion 
The focus of this study was to investigate the potential role of an interaction between 
Tbx2 and Uspl in transcriptional regulation. Since such a role was not observed, some 
preliminary work was done to investigate other potential roles to understand the significance 
of the interaction between Tbx2 and Usp 1. Both Tbx2 and deubiquitination (DUB) enzymes 
have been reported to regulate cell proliferation. Tbx2 was reported to down-regulate 
Cdkn2a promoter activity and bypass cellular arrest (Jacobs et al., 2000). Furthermore, Tbx2 
repressed p21WAF1 expression, which resulted in increased proliferation of human melanoma 
cells (Vance et al., 2005). Constitutive expression of DUB-1 was reported to cause cellular 
arrest at G1 (Zhu et al., 1996). On the other hand, knock-down of UBPY by anti-sense RNA 
expression inhibited cell cycle progression (Naviglio et al., 1998). In addition, a catalytically 
inactive form of Ubp-M (Uspl6) co-localized to mitotic chromatin and led to cellular arrest 
and apoptosis, which indicated that DUB activity was required for cell cycle control (Cai et 
al., 1999). Taken together these results indicate that Tbx2 and Uspl may be involved in the 
regulation of cellular proliferation. 
To test the hypothesis that an interaction between Tbx2 and Uspl regulates cell 
proliferation, stable Cos? cell populations were generated that expressed empty control 
vector, Tbx2, Uspl, Uspl-C90S or Uspl-c. In addition, cell populations were established 
that co-expressed Tbx2 with Uspl, Uspl-C90s, or Uspl-c. Cells were plated at a low cell-
density, grown for 24 hour then treated with BrdU for four hours. Cells were then scored for 
BrdU incorporation, indicative of cellular proliferation (Tables la-b). 
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Replicate 1 I 2 I 3 | 
T reatment Field Cells FITC + 
% 
FITC Cells 
FITC 
+ 
% 
FITC Cells FITC + % FITC 
1 14 6 42.9 10 7 70.0 10 3 30.0 
1=pcDNA3 2 11 9 81.8 4 2 50.0 3 3 100.0 3 6 1 16.7 6 4 66.7 22 14 63.6 
4 5 3 60.0 6 3 50.0 9 5 55.6 
5 13 11 84.6 9 7 77.8 15 10 66.7 
6 9 5 55.6 5 4 80.0 9 4 44.4 
7 18 11 61.1 18 9 50.0 2 2 100.0 
8 9 4 44.4 3 3 100.0 29 11 37.9 
9 8 3 37.5 9 7 77.8 8 3 37.5 
10 14 5 35.7 5 3 60.0 4 3 75.0 
Total 107 58 5^2 75 49 6&3 111 58 523 
1 13 4 30.8 6 3 50.0 9 4 44.4 
2=Tbx2 2 16 11 68.8 9 5 55.6 9 8 88.9 3 15 6 40.0 13 9 69.2 10 5 50.0 
4 10 3 30.0 6 3 50.0 22 7 31.8 
5 10 4 40.0 5 4 80.0 7 1 14.3 
6 6 4 66.7 9 7 77.8 14 13 92.9 
7 3 2 66.7 3 3 100.0 10 8 80.0 
8 10 4 40.0 14 5 35.7 21 13 61.9 
9 4 4 100.0 4 1 25.0 8 6 75.0 
10 6 3 50.0 2 2 100.0 13 5 38.5 
^^Tota^^ 93 45 4^4 7j1 42 59.2 123J  7() 5&9 
1 4 3 75.0 13 8 61.5 16 14 87.5 
3=USP1 2 22 12 54.5 20 11 55.0 17 10 58.8 3 7 2 28.6 19 6 31.6 11 6 54.5 
4 4 4 100.0 16 7 43.8 9 7 77.8 
5 5 4 80.0 17 11 64.7 9 5 55.6 
6 9 6 66.7 17 8 47.1 32 18 56.3 
7 11 5 45.5 10 6 60.0 38 19 50.0 
8 10 8 80.0 17 8 47.1 5 5 100.0 
9 13 5 38.5 13 8 61.5 8 5 62.5 
10 11 8 72.7 29 9 31.0 11 5 45.5 
^TTota^^  96 57 5SL4 171 82 156 94 
1 6 4 66.7 7 5 37 20 
4=USP1:C90S 2 8 2 25.0 19 8 42.1 19 6 31.6 3 5 5 100.0 5 4 80.0 14 8 57.1 
4 17 11 64.7 15 9 60.0 16 4 25.0 
5 20 11 55.0 23 10 43.5 5 5 100.0 
6 17 4 23.5 17 8 47.1 15 12 80.0 
7 17 12 70.6 17 6 35.3 12 11 91.7 
8 12 7 58.3 15 10 66.7 26 10 38.5 
9 11 6 54.5 16 9 56.3 15 11 73.3 
10 11 8 72.7 13 7 53.8 8 5 62.5 
Total 124 70 56.5 147 76 51.7 167 92 55.1 
Table la: Proliferation Assay. Treatments are indicated in the left column. Each 
treatment was replicated three times. Ten fields per replicate were scored for total 
cells per field (cells) and the number of FITC positive cells (FITC +). The presence 
of FITC identified cells that had incorporated BrdU, indicative of proliferation. 
(%FITC) - (FITC+/Cells). 
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Replicate 1 2 3 
Treatment Field Cells FITC + 
% 
FITC Cells 
FITC 
+ 
% 
FITC Cells FITC + % FITC 
1 20 11 55.0 32 9 28.1 30 15 50.0 
5=pSuperand 2 5 3 60.0 35 13 37.1 16 10 62.5 
USP1-C 3 18 12 66.7 8 3 37.5 20 12 60.0 
4 14 6 42.9 16 6 37.5 6 1 16.7 
5 10 5 50.0 28 21 75.0 5 5 100.0 
6 11 6 54.5 12 7 58.3 23 10 43.5 
7 3 3 100.0 18 9 50.0 12 7 58.3 
8 15 8 53.3 29 16 55.2 13 9 69.2 
9 11 6 54.5 16 6 37.5 18 15 83.3 
10 9 8 88.9 14 10 71.4 17 13 76.5 
Total 116 68 58.6 208 100 48.1 160 97 60.6 
1 22 16 72.7 7 6 85.7 18 16 88.9 
6=Tbx2 and 2 19 11 57.9 16 7 43.8 9 4 44.4 
USP1 3 21 10 47.6 8 6 75.0 11 5 45.5 
4 14 9 64.3 6 2 33.3 6 4 66.7 
5 17 9 52.9 8 4 50.0 31 16 51.6 
6 20 10 50.0 20 6 30.0 10 4 40.0 
7 20 16 80.0 7 6 85.7 25 10 40.0 
8 22 11 50.0 19 11 57.9 14 10 71.4 
9 20 9 45.0 21 12 57.1 10 2 20.0 
10 32 17 53.1 25 14 56.0 13 5 38.5 
Total 207 118 57.0 137 74 54.0 147 76 51.7 
1 11 7 63.6 13 8 61.5 8 5 62.5 
7=Tbx2 and 2 7 6 85.7 8 5 62.5 11 9 81.8 
USP1:C90S 3 7 5 71.4 9 7 77.8 17 13 76.5 
4 4 2 50.0 9 6 66.7 8 6 75.0 
5 8 6 75.0 9 6 66.7 5 3 60.0 
6 7 4 57.1 19 13 68.4 9 8 88.9 
7 8 4 50.0 5 4 80.0 12 5 41.7 
8 11 7 63:6 16 10 62.5 13 11 84.6 
9 24 13 54.2 8 8 100.0 8 5 62.5 
10 19 9 47.4 6 4 66.7 17 7 41.2 
Total 106 63 59.4 102 71 69.6 108 72 66.7 
1 8 6 75.0 3 2 66.7 7 5 71.4 
8=Tbx2 and 2 13 7 53.8 3 1 33.3 2 2 100.0 
pSuperUSP1-c 3 8 4 50.0 6 3 50.0 2 2 100.0 
4 16 6 37.5 14 5 35.7 3 3 100.0 
5 1 1 100.0 4 3 75.0 6 4 66.7 
6 12 6 50.0 6 2 33.3 7 5 71.4 
7 5 5 100.0 5 5 100.0 3 3 100.0 
8 5 3 60.0 4 3 75.0 4 4 100.0 
9 7 4 57.1 7 2 28.6 3 2 66.7 
10 16 11 68.8 3 3 100.0 3 1 33.3 
Total 91 53 58.2 55 29 52.7 40 31 77.5 
Table lb: Proliferation Assay. Treatments are indicated in the left column. Each 
treatment was replicated three times. Ten fields per replicate were scored for total 
cells per field (cells) and the number of FITC positive cells (FITC +). The presence 
of FITC identified cells that had incorporated BrdU, indicative of proliferation. 
(%FITC) = (FITC+/Cells). 
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Tbx2 has been shown to inhibit cellular senescence and maintain proliferation in both 
breast cancer, and melanoma cell lines (Jacobs et al., 2000; Vance et al., 2005). Furthermore, 
loss of Tbx2 function, by expression of either a Tbx2 dominant negative or Tbx2 siRNA, 
resulted in a reduction of cellular proliferation rate (Vance et al., 2005). In this preliminary 
study, proliferation of Cos? cells appeared to be unaffected by the expression of Tbx2. 
However, the initial experiment reported here was designed to investigate differences in the 
rate of cellular proliferation. Although, loss of Tbx2 led to a reduced proliferation rate of 
B16 melanoma cells (Vance et al., 2005), MCF-7 cells that over-expressed Tbx2 appeared to 
proliferate at a constant rate (Jacobs et al., 2000). Therefore, to fully explore the role of 
Tbx2 in the cellular proliferation of Cos? cells, loss of function experiments designed to 
reduce or remove Tbx2 from the cells should be performed. 
Although several DUB enzymes have shown to regulate cellular proliferation, Nijman 
and colleagues (2005) recently reported that knock-down of Uspl by siRNA did not appear 
to affect cell-cycle progression. The initial results obtained here, likewise gave no indication 
that Uspl, either alone or in combination with Tbx2, could affect cellular proliferation. 
Taken together, these data tend to indicate that cellular proliferation was not affected by 
Uspl. However, as suggested above for Tbx2, a cell line with established over-expression of 
Uspl, rather than a mixed population, should be generated. To explore the interaction of 
Tbx2 and Uspl in cellular proliferation, a similar line that over-expresses both Tbx2 and 
Uspl could be established. Alternatively, a role for the interaction between Tbx2 and Uspl 
in cellular proliferation could be investigated in MCF-7 (Jacobs et al., 2000) or B16 (Vance 
et al., 2005) cell lines, where Tbx2 is endogenously over-expressed and has been previously 
shown to regulate cellular proliferation. 
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Uspl May Affect Cellular Localization ofTbx2 
Tbx2 expression was observed in both the nucleus and the cytoplasm (Fig. 2b-c). It 
was suggested that a phosphorylation event may be responsible for shuttling Tbx2 between 
the two cellular compartments (Gibert and Begemann, 2002), but to date such an event has 
not been described. Ubiquitination and deubiquitination have also been shown to affect the 
cellular localization of proteins (reviews by Wing et al., 2003; Shcherbik and Haines, 2004). 
To investigate a potential role for Uspl in the cellular localization of Tbx2, Cos7 cells 
were co-transfected with pcDNA3:Tbx2 and either pEGFP-Cl or pGFP:Uspl. Cells were 
fixed and incubated with Tbx2 antibody. Tbx2 expression was visualized with Alexa594 
fluorescence probe conjugated to anti-rabbit secondary antibody. Localization of Tbx2 was 
analyzed by IF in the presence or absence of GFP:Uspl co-expression. Cells that expressed 
GFP, but not Tbx2 were omitted from this analysis since it could not be determined whether 
the absence of Tbx2 was due to Uspl activity or to lack of Tbx2 transaction into the cell. 
Individual GFP and Tbx2 positive cells were counted and cells were scored for subcellular 
localization of Tbx2 (Tables 2a-b). In the GFP control treatments, fewer cells appeared to 
have Tbx2 localized in the nucleus. Approximately 17% of the cells scored appeared to be 
predominantly nuclear, while 87% had Tbx2 either in the cytoplasm, or diffused throughout 
the entire cell. In contrast, approximately 43% of cells that expressed GFP:Uspl fusion 
protein appeared to have Tbx2 localized in the nucleus (Table 2b; Fig. 3). This initial result 
indicated that the nuclear localization of Tbx2 may have been affected by the presence of 
Uspl. Alternatively, Uspl may have cleaved a polyubiquitin signal that marked Tbx2 for 
nuclear export and degradation by the proteasome. The potential failure of Tbx2 to be 
degraded and recycled could have led to its accumulation within the nucleus. 
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GFP Tbx2 Localization 
GFP Nuclear Cytoplasmic Both Tbx2 Cells %Nuclear %Non-nuclear 
+ + + + -
Included isolated cells 
6 0 0 6 0 6 0.0 100.0 
3 1 0 2 0 3 33.3 66.7 
11 0 0 11 0 11 0.0 100.0 
7 3 0 4 0 7 42.9 57.1 
9 0 0 9 0 9 0.0 100.0 
9 0 2 4 3 6 0.0 100.0 
8 2 1 4 1 7 28.6 71.4 
10 2 1 7 0 10 20.0 80.0 
9 2 0 7 0 9 22.2 77.8 
6 0 0 6 0 6 0.0 100.0 
10 1 0 9 0 10 10.0 90.0 
9 2 0 7 0 9 22.2 77.8 
7 0 0 7 0 7 0.0 100.0 
4 2 2 0 0 4 50.0 50.0 
5 0 0 5 0 5 0.0 100.0 
10 0 0 10 0 10 0.0 100.0 
4 1 0 3 0 4 25.0 75.0 
5 1 0 3 1 4 25.0 75.0 
4 1 0 3 0 4 25.0 75.0 
4 1 0 3 0 4 25.0 75.0 
6 0 1 4 1 5 0.0 100.0 
7 3 1 3 0 7 42.9 57.1 
6 2 2 1 1 5 40.0 60.0 
7 1 0 6 0 7 14.3 85.7 
9 2 0 7 0 9 22.2 77.8 
9 0 0 9 0 9 0.0 100.0 
8 4 0 4 0 8 50.0 50.0 
192 31 10 144 7 185 16.8 83.2 
Table 2a. Scoring of GFP positive cells and Tbx2 localization (Raw Data). GFP 
positive cells were identified and analyzed for Tbx2 localization. Tbx2 localization was 
scored as either nuclear, cytoplasmic or both. Tbx2- indicates the number of GFP 
positive cells omitted from the study because Tbx2 expression was not detected. "Cells 
included" refers to the total number of GFP cells from each field retained in the study. 
Tbx2 localization percentages were calculated for each field, and for the whole 
experiment. Totals for the entire experiment are in bold. (%Nuclear=Nuclear/Cells 
Included; %Non-nuclear=(Cytoplasmic + Both)/Cells Included). 
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GFP-
USP1 Tbx2 Localization 
GFP 
+ 
Nuclear 
+ 
Cytoplasmic 
+ 
Nucl/Cyto 
+ 
Tbx2 Cells 
Included 
%nuclear %Non-nuclear 
isolated cells 
6 3 0 2 1 5 60.0 40.0 
12 4 0 6 2 10 40.0 60.0 
9 6 0 2 1 8 75.0 25.0 
14 4 0 3 7 7 57.1 42.9 
10 3 0 2 5 5 60.0 40.0 
9 6 2 0 1 8 75.0 25.0 
7 2 0 3 2 5 40.0 60.0 
10 1 2 4 3 7 14.3 85.7 
6 1 1 4 0 6 16.7 83.3 
8 4 0 4 0 8 50.0 50.0 
12 1 3 6 2 10 10.0 90.0 
6 2 0 4 0 6 33.3 66.7 
2 1 0 1 0 2 50.0 50.0 
9 3 0 3 3 6 50.0 50.0 
2 0 0 2 0 2 0.0 100.0 
10 5 0 3 2 8 62.5 37.5 
10 2 0 5 3 7 28.6 71.4 
8 2 0 6 0 8 25.0 75.0 
5 3 0 2 0 5 60.0 40.0 
7 4 0 1 2 5 80.0 20.0 
13 6 0 7 0 13 46.2 53.8 
7 1 3 1 2 5 20.0 80.0 
6 1 3 2 0 6 16.7 83.3 
9 2 1 2 4 5 40.0 60.0 
12 4 3 1 4 8 50.0 50.0 
8 3 2 0 3 5 60.0 40.0 
217 74 20 76 47 170 43.5 56.5 
Table 2b. Scoring of GFP:Uspl positive cells and Tbx2 localization. GFP:Uspl positive 
cells were identified and analyzed for Tbx2 localization. Tbx2 localization was scored 
as either nuclear, cytoplasmic or both. Tbx2- indicates the number of GFP positive cells 
omitted from the study because Tbx2 expression was not detected. "Cells included" 
refers to the total number of GFP cells from each field retained in the study. Tbx2 
localization percentages were calculated for each field, and for the whole experiment. 
Totals for the entire experiment are in bold. (%Nuclear=Nuclear/Cells Included; 
%Non-nuclear=(Cytoplasmic + Both)/Cells Included). 
Figure 1. Cellular localization of 
Tbx2. A. Nuclei are visualized by 
Hoescht 33258 labeling. B. Tbx2 was 
expressed found in both the nucleus and 
the cytoplasm of transiently transfected 
Cos? cells. C. Tbx2 overlaid with 
Hoescht staining to illustrate both 
nuclear and cytoplasmic expression of 
Tbx2. White arrows indicate nuclear 
Tbx2 expression and black arrows 
indicate cytoplasmic Tbx2 expression. 
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In the delineation of the interactive domain within Uspl that bound Tbx2 it was 
shown that Tbx2 interacted with second UCH domain of Uspl. The two UCH domains 
found in DUB proteins have been shown to fold together to form the active site where 
deubiquitination takes place (Hu et al., 2002). The location of this interaction, therefore, 
would indicate that Uspl may deubiquitinate Tbx2. Localization of Tbx2 within the cell, 
therefore, may depend upon ubiquitination/deubiquination events. However, Tbx2 has not 
yet been found in a ubiquitinated state. 
Alternatively, the nuclear-cytoplasmic shuttling of Tbx2 may indeed depend upon a 
phosphorylation event, as has been suggested (Gibert and Begemann, 2002). Recently, 
Krappman and Scheidereit (2005) reviewed signaling events of the NFKB pathway that 
involved ubiquitin. They discussed the emerging roles of ubiquitination and deubiquitination 
on the activation of the IKB kinase complex, and subsequent localization of NFKB to the 
nucleus. A similar line of events may take place here, in which Uspl induces the activation 
of a kinase that in turn phosphorylates Tbx2, thereby targeting it to the nucleus. 
References 
Cai, S., Babbitt, R.W., Marchesi, V.T. 1999. A mutant deubiquitinating enzyme (Ubp-M) 
associates with mitotic chromosomes and blocks cell division. PNAS. 96: 2828-2833. 
Gibert, Y. and Begemann, G. 2002. Variations on a T: orchestration of T-box signalling in 
development. Trends Genet. 18: 615-616. 
Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J., Gu., W., Cohen, R. and Shi, Y. 2002. Crystal 
Structure of a UBP-Family Deubiquitinating Enzyme in Isolation and in Complex 
with Ubiquitin Aldehyde. Cell. Ill: 1041-1054 
Jacobs, J.J., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P.M., 
van Welsem, T., van de Vijver, M., Koh, E., Daley, G. and van Lohuizen, M., 2000. 
Senescence bypass screen identifies TBX2, which represses Cdkn2a (pl9(ARF)) and 
is amplified in a subset of human breast cancers. Nat Genet. 26: 291-299. 
Krappman, D. and Scheidereit, C. 2005. A pervasive role of ubiquitin conjugation in 
activation and termination of IkappaB kinase pathways. EMBO Rep. 6: 321-326. 
Naviglio, S., Mattecucci, C., Matoskova, B., Nagase, T., Nomura, N., Di Fiore, P.P. and 
Draetta, G.F. 1998. UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO 
J. 17: 3241-3250. 
Nijman, S.M., Huang, T.T., Dirac, A.M., Brummelkamp, T.R., Kerkhoven, R.M., D'Andrea, 
A.D. and Bernards, R. 2005. The deubiquitinating enzyme Uspl regulates the 
Fanconi anemia pathway. Mol Cell. 17: 331-339. 
Shcherbik, N. and Haines, D.S. 2004. Ub on the move. J Cell Biochem. 93: 11-19. 
Vance, K.W., Carreira, S., Brosch, G. and Goding, C.R. 2005. Tbx2 is overexpressed and 
plays an important role in maintaining proliferation and suppression of senescence in 
melanomas. Cancer Res. 65: 2260-2268. 
Wing, S.S. 2003. Deubiquitinating enzymes-the importance of driving in reverse along the 
ubiquitin-proteasome pathway. Int J Biochem Cell Biol. 35: 590-605. 
Zhu, Y., Carroll, M., Papa, FR., Hochstrasser, M. and D'Andrea, A.D. 1996. DUB-1, a 
deubiquitinating enzyme with growth-suppressing activity. PNAS. 93: 3275-3279. 
137 
Acknowledgements 
. I would like to thank those who have had a hand in helping me to achieve this honor. Thank 
you to Dr. Jim Reecy, my major professor, for giving me the opportunity to work on this 
project. I am also grateful for your moments of encouragement and understanding. 
Thank you Jo Anne Powell-Coffman for your honesty, and for helping me to keep my sanity. 
A special thank you to Karen Langner and Mary Sue Mayes for your help in the lab, for your 
stimulating conversations and for your friendships. 
Thank you James Koltes for your input and analysis of manuscript drafts that you suffered 
through for me. 
Thank you to Samantha Anderson, Cari Steelman, and Jose Rodriguez for you thoughts, 
advice, ideas and friendships. 
I also want to thank Dr. David Kooyman who introduced me to the world of molecular 
biology and showed me how fun research can actually be. 
A special thanks to my family both near and far for their loving support, their faith in me, and 
their prayers on my behalf that I have felt across the distance. 
